SANUWAVE Health (SNWV) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 24, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'SANUWAVE Health, Inc.	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	46,796,519	'
Entity Public Float	'	'	$5,300,000
Amendment Flag	'false	'	'
Entity Central Index Key	'0001417663	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS	'	'
Cash and cash equivalents	$182,315	$70,325
Accounts receivable - trade, net of allowance for doubtful accounts of $43,282 in 2013 and $44,124 in 2012	139,736	87,826
Inventory (Note 2)	246,006	292,665
Prepaid expenses	75,020	128,495
TOTAL CURRENT ASSETS	643,077	579,311
PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation (Note 3)	13,267	32,842
OTHER ASSETS	11,444	11,358
INTANGIBLE ASSETS, at cost, less accumulated amortization (Note 4)	920,269	1,227,025
TOTAL ASSETS	1,588,057	1,850,536
CURRENT LIABILITIES	'	'
Accounts payable	935,028	555,898
Accrued expenses (Note 5)	863,572	721,916
Accrued employee compensation	140,102	534,659
Convertible promissory note (Note 6)	147,775	'
Promissory notes (Note 7)	89,038	'
Interest payable, related parties (Note 10)	163,729	81,864
Capital lease payable, current portion (Note 14)	3,951	4,933
Liabilities related to discontinued operations (Note 9)	'	655,061
TOTAL CURRENT LIABILITIES	2,343,195	2,992,847
NON-CURRENT LIABILITIES	'	'
Notes payable, related parties (Note 10)	5,372,743	5,372,743
Capital lease payable, non-current portion (Note 14)	'	3,951
TOTAL NON-CURRENT LIABILITIES	5,372,743	5,376,694
TOTAL LIABILITIES	7,715,938	8,369,541
STOCKHOLDERS' DEFICIT	'	'
COMMON STOCK, par value $0.001, 150,000,000 shares authorized; 37,984,182 and 21,007,536 issued and outstanding at December 31, 2013 and 2012, respectively (Note 12)	37,984	21,008
ADDITIONAL PAID-IN CAPITAL	76,037,490	64,357,193
ACCUMULATED OTHER COMPREHENSIVE INCOME	6,688	13,116
ACCUMULATED DEFICIT	-82,210,043	-70,910,322
TOTAL STOCKHOLDERS' DEFICIT	-6,127,881	-6,519,005
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,588,057	1,850,536
Subscription Payable For Senior Secured Convertible Promissory Notes [Member]	'	'
CURRENT LIABILITIES	'	'
Subscriptions payable for Senior Secured Notes (Note 8)	'	$438,516

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts Receivable, Allowance for Doubtful Accounts (in Dollars)	$43,282	$44,124
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in Dollars per share)	$0.00	$0.00
Common Stock, shares authorized	150,000,000	150,000,000
Common Stock, shares issued	37,984,182	21,007,536
Common Stock, shares outstanding	37,984,182	21,007,536

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
REVENUE	$800,029	$769,217
COST OF REVENUE	189,791	220,257
GROSS PROFIT	610,238	548,960
OPERATING EXPENSES	'	'
Research and development	2,296,662	1,762,194
General and administrative	3,963,206	4,521,957
Depreciation	19,575	20,375
Amortization	306,756	306,757
TOTAL OPERATING EXPENSES	6,586,199	6,611,283
OPERATING LOSS	-5,975,961	-6,062,323
OTHER INCOME (EXPENSE)	'	'
Loss on embedded conversion feature of Senior Secured Notes (Note 8)	-2,373,813	'
Loss on extinguishment of Senior Secured Notes (Note 8)	-1,073,572	'
Interest expense, net	-360,273	-323,227
Gain on sale of fixed assets	7,500	'
Loss on foreign currency exchange	-273	-7,428
TOTAL OTHER INCOME (EXPENSE)	-5,978,821	-339,171
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	-11,954,782	-6,401,494
INCOME TAX EXPENSE	0	0
LOSS FROM CONTINUING OPERATIONS	-11,954,782	-6,401,494
DISCONTINUED OPERATIONS (Note 9)	'	'
Gain on discontinued operations liabilities adjustment, net of tax	655,061	'
INCOME FROM DISCONTINUED OPERATIONS	655,061	'
NET LOSS	-11,299,721	-6,401,494
OTHER COMPREHENSIVE INCOME (LOSS)	'	'
Foreign currency translation adjustments	-6,428	2,650
TOTAL COMPREHENSIVE LOSS	-11,306,149	-6,398,844
LOSS PER SHARE:	'	'
Loss from continuing operations - basic and diluted (in Dollars per share)	($0.42)	($0.30)
Income from discontinued operations - basic and diluted (in Dollars per share)	$0.02	'
Net loss - basic and diluted (in Dollars per share)	($0.40)	($0.30)
Weighted average shares outstanding - basic and diluted (in Shares)	28,132,134	20,915,869
Senior Secured Notes [Member]	'	'
OTHER INCOME (EXPENSE)	'	'
Accretion of interest and interest expense on Senior Secured Notes (Note 8)	($2,178,390)	($8,516)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Deficit (USD $)	Public Offering [Member]	Public Offering [Member]	Public Offering [Member]	Private Placements [Member]	Private Placements [Member]	Private Placements [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
	Common Stock [Member]	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]
Balances as of December 31 at Dec. 31, 2011	'	'	'	'	'	'	$20,908	$62,940,977	($64,508,828)	$10,466	($1,536,477)
Balances as of December 31 (in Shares) at Dec. 31, 2011	'	'	'	'	'	'	20,907,536	'	'	'	'
Net loss	'	'	'	'	'	'	'	'	-6,401,494	'	-6,401,494
Shares issued under subscription agreement	'	'	'	'	'	'	100	24,900	'	'	25,000
Shares issued under subscription agreement (in Shares)	'	'	'	'	'	'	100,000	'	'	'	'
Stock-based compensation - options	'	'	'	'	'	'	'	1,391,316	'	'	1,391,316
Foreign currency translation adjustment	'	'	'	'	'	'	'	'	'	2,650	2,650
Balances as of December 31 at Dec. 31, 2012	'	'	'	'	'	'	21,008	64,357,193	-70,910,322	13,116	-6,519,005
Balances as of December 31 (in Shares) at Dec. 31, 2012	'	'	'	'	'	'	21,007,536	'	'	'	'
Net loss	'	'	'	'	'	'	'	'	-11,299,721	'	-11,299,721
Shares issued in Senior Secured Notes conversion	'	'	'	'	'	'	10,934	6,549,785	'	'	6,560,719
Shares issued in Senior Secured Notes conversion (in Shares)	'	'	'	'	'	'	10,934,533	'	'	'	'
Warrants issued in Senior Secured Notes conversion	'	'	'	'	'	'	'	1,073,572	'	'	1,073,572
Shares issued	3,007	1,514,443	1,517,450	1,043	625,145	626,188	'	'	'	'	'
Shares issued (in Shares)	3,006,818	'	'	1,043,646	'	'	'	'	'	'	'
Shares issued under subscription agreement	'	'	'	'	'	'	300	74,700	'	'	75,000
Shares issued under subscription agreement (in Shares)	'	'	'	'	'	'	300,000	'	'	'	'
Shares issued for services	'	'	'	'	'	'	1,584	1,012,683	'	'	1,014,267
Shares issued for services (in Shares)	'	'	'	'	'	'	1,583,315	'	'	'	'
Shares issued for stock option exercise	'	'	'	'	'	'	108	37,809	'	'	37,917
Shares issued for stock option exercise (in Shares)	'	'	'	'	'	'	108,334	'	'	'	108,334
Stock-based compensation - options	'	'	'	'	'	'	'	792,160	'	'	792,160
Foreign currency translation adjustment	'	'	'	'	'	'	'	'	'	-6,428	-6,428
Balances as of December 31 at Dec. 31, 2013	'	'	'	'	'	'	$37,984	$76,037,490	($82,210,043)	$6,688	($6,127,881)
Balances as of December 31 (in Shares) at Dec. 31, 2013	'	'	'	'	'	'	37,984,182	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($11,299,721)	($6,401,494)
Gain on discontinued operations liabilities adjustment	-655,061	'
Loss from continuing operations	-11,954,782	-6,401,494
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities	'	'
Amortization	306,756	306,757
Depreciation	19,575	20,375
Change in allowance for doubtful accounts	-842	-30,728
Stock-based compensation - employees, directors and advisors	792,160	1,391,316
Stock issued for consulting services	1,014,267	'
Loss on embedded conversion feature of Senior Secured Notes	2,373,813	'
Loss on extinguishment of Senior Secured Notes	1,073,572	'
Gain on sale of property and equipment	-7,500	'
Changes in assets - (increase)/decrease	'	'
Accounts receivable - trade	-51,068	24,467
Inventory	46,659	103,619
Prepaid expenses	53,475	34,480
Due from Pulse Veterinary Technologies, LLC	'	27,837
Other	-86	-8,166
Changes in liabilities - increase/(decrease)	'	'
Accounts payable	379,130	-200,759
Accrued employee compensation	-394,557	-97,674
Accrued expenses	141,656	531,333
Promissory notes - accrued interest	23,313	8,516
Interest payable	81,865	'
NET CASH USED BY OPERATING ACTIVITIES	-3,924,204	-4,290,121
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Sale of property and equipment	7,500	'
Purchase of property and equipment	'	-2,011
NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES	7,500	-2,011
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from subscriptions payable for Senior Secured Notes	1,570,000	430,000
Proceeds from Public Offering, net	1,517,450	'
Proceeds from Private Placements	626,188	'
Proceeds from promissory notes	538,500	'
Proceeds from sale of capital stock - subscription agreement	75,000	25,000
Proceeds from employee stock option exercise	37,917	'
Payments of principal on promissory notes	-325,000	'
Payments of principal on capital lease	-4,933	-4,576
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,035,122	450,424
EFFECT OF EXCHANGE RATES ON CASH	-6,428	2,650
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	111,990	-3,839,058
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	70,325	3,909,383
SUPPLEMENTAL INFORMATION	'	'
Cash paid for interest, related parties	242,904	324,768
Cash paid for capital lease interest	530	858
CASH AND CASH EQUIVALENTS, END OF PERIOD	182,315	70,325
Senior Secured Notes [Member]	'	'
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities	'	'
Accretion of interest and accrued interest on Senior Secured Notes	$2,178,390	'

Note_1_Summary_of_Significant_

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	(1)     Summary of significant accounting policies
	Description of the business – SANUWAVE Health, Inc. and subsidiaries (the "Company") is a shockwave technology company using noninvasive, high energy, acoustic shockwaves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive, acoustic shockwaves to solicit a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the demaPACE device for treating diabetic foot ulcers which is in a supplemental Phase III clinical study with possible FDA approval in 2015 subject to submission of satisfactory clinical study results.
	The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company intends to apply its Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions. The Company is currently not marketing any commercial products in the United States. Revenue is from sales of the European Conformity Marking (“CE Mark”) devices and accessories in Europe, Canada and Asia/Pacific.
	Financial Condition – Since inception in 2005, the Company’s operations have primarily been funded from the sale of capital stock and convertible debt securities. At December 31, 2013, the Company had cash and cash equivalents totaling $182,315 and a net working capital deficit of $1,700,118.  Subsequent to year-end, on March 17, 2014, the Company completed a private offering of securities for an aggregate total purchase price of $9,280,000 (see Note 19). In addition, the Company raised $815,000 through the issuance of unsecured 18% convertible promissory notes in the first quarter of 2014, which by their terms, converted into equity at the same terms as the private offering on March 17, 2014.
	The Company does not currently generate significant recurring revenue and will require additional capital in the second half of 2015 to commercialize the dermaPACE, assuming positive clinical study results and FDA approval. Although no assurances can be given, management of the Company believes that existing capital resources should enable the Company to fund operations for at least the next twelve months. Accordingly, the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
	The significant accounting policies followed by the Company are summarized below:
	Foreign currency translation - The functional currencies of the Company’s foreign operations are the local currencies. The financial statements of the Company’s foreign subsidiary have been translated into United States dollars in accordance with ASC 830, Foreign Currency Matters (formerly SFAS No. 52, Foreign Currency Translation.) All balance sheet accounts have been translated using the exchange rates in effect at the balance sheet date. Income statement amounts have been translated using the average exchange rate for the year. Translation adjustments are reported in other comprehensive income in the consolidated statements of comprehensive loss and as cumulative translation adjustments as a separate component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders’ deficit.
	Principles of consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
	Estimates – These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America. Because a precise determination of assets and liabilities, and correspondingly revenue and expenses, depend on future events, the preparation of consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These consolidated financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein. Significant estimates include the recording of allowances for doubtful accounts, estimated reserves for inventory, estimated useful life of property and equipment, accrued expenses, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation and the estimated fair value of intangible assets.
	Cash and cash equivalents - For purposes of the consolidated financial statements, liquid instruments with an original maturity of 90 days or less are considered cash and cash equivalents. The Company maintains its cash in bank accounts which may exceed federally insured limits.
	Concentration of credit risk and limited suppliers - Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. Two distributors accounted for 28% and 22% of revenue for the year ended December 31, 2013, and 20% and 29% of revenue for the year ended December 31, 2012. The two distributors accounted for 10% and 11% of accounts receivable at December 31, 2013, and 6% and 35% of accounts receivable at December 31, 2012.
	We depend on suppliers for product component materials and other components that are subject to stringent regulatory requirements. We currently purchase most of our product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may be difficult to arrange a replacement supplier because certain of these materials may only be available from one or a limited number of sources. In addition, establishing additional or replacement suppliers for these materials may take a substantial period of time, as certain of these suppliers must be approved by regulatory authorities.
	Accounts receivable - Accounts receivable are stated at the amount management expects to collect from outstanding balances. Management provides for probable uncollectible amounts through a charge to earnings based on its assessment of the current status of individual accounts. Receivables are generally considered past due if greater than 60 days old. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts.
	Inventory - Inventory consists of finished medical equipment and parts and is stated at the lower of cost or market, which is valued using the first in, first out (“FIFO”) method. Market is based upon realizable value less allowance for selling and distribution expenses. The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete.
	Depreciation of property and equipment - The straight-line method of depreciation is used for computing depreciation on property and equipment. Depreciation is based on estimated useful lives as follows: machines and equipment, 3 years; office and computer equipment, 3 years; furniture and fixtures, 3 years; vehicles, 3 years; and software, 2 years.
	Intangible assets - Intangible assets subject to amortization consist of patents which are recorded at cost. Patents are amortized on a straight-line basis over the average life of 11.4 years. The Company regularly reviews intangible assets to determine if facts and circumstances indicate that the useful life is shorter than the Company originally estimated or that the carrying amount of the assets may not be recoverable. Factors the Company considers important and could trigger an impairment review include the following:
		●	Significant delays or obstacles encountered in the dermaPACE device clinical trial and PMA application;
		●	Significant changes in the manner in which the Company uses its assets or significant changes in the Company’s overall business strategy; and
		●	Significant underperformance of the Company’s assets relative to future operating results.
	If such facts and circumstances exist, the Company assesses the recoverability of the intangible assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds its fair value.
	Fair value of financial instruments - The book values of accounts receivable, accounts payable, and other financial instruments approximate their fair values, principally because of the  short-term maturities of these instruments.
	The Company has adopted ASC 820-10, Fair Value Measurements (formerly SFAS No. 157), which defines fair value, establishes a framework for measuring fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements.
	The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and  requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:
	Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for  identical assets and liabilities;
	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for  the asset or liability, either directly or indirectly; and
	Level 3 - Unobservable inputs that are not corroborated by market data, therefore  requiring the Company to develop its own assumptions.
	The Company’s notes payable, related parties consist of $5,372,743 of principal at December 31, 2013 and 2012. Interest accrues on the notes at a rate of six percent (6%) per annum. The fair value was determined using estimated future cash flows discounted at current rates, which is a Level 3 measurement. The estimated fair value of the Company’s notes payable, related parties was $4,653,780 and $4,545,620 at December 31, 2013 and 2012, respectively.
	Impairment of long-lived assets – The Company reviews long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts of the assets may not be recoverable. An impairment loss is recognized only if the carrying amount of the asset is not recoverable and exceeds its fair value. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the asset’s carrying value is not recoverable, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds its fair value. The Company determines fair value by using a combination of comparable market values and discounted cash flows, as appropriate.
	Revenue recognition - Sales of medical devices, including related applicators and applicator kits, are recognized when shipped to the customer. Shipments under agreements with distributors are invoiced at a fixed price, are not subject to return, and payment for these shipments is not contingent on sales by the distributor. The Company recognizes revenue on shipments to distributors in the same manner as with other customers. Fees from services performed are recognized when the service is performed.
	Shipping and handling costs - Shipping charges billed to customers are included in revenue. Shipping and handling costs have been recorded in cost of revenue.
	Income taxes - Income taxes are accounted for utilizing the asset and liability method prescribed by the provisions of ASC 740, Income Taxes (formerly SFAS No. 109, Accounting for Income Taxes). Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided for the deferred tax assets, including loss carryforwards, when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
	A provision of ASC 740, Income Taxes (formerly FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48)) specifies the way public companies are to account for uncertainties in income tax reporting, and prescribes a methodology for recognizing, reversing, and measuring the tax benefits of a tax position taken, or expected to be taken, in a tax return. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions would “more-likely-than-not” be sustained if challenged by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold would be recorded as a tax benefit or expense in the current year.
	The Company will recognize in income tax expense interest and penalties related to income tax matters. For the years ended December 31, 2013 and 2012, the Company did not have any amounts recorded for interest and penalties.
	Loss per share - The Company calculates net income (loss) per share in accordance with ASC 260, Earnings Per Share (formerly SFAS No. 128, Earnings Per Share).  Under the provisions of ASC 260, basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of shares of common stock outstanding for the period.  Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents then outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share. As a result of the net loss for the years ended December 31, 2013 and 2012, respectively, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. The anti-dilutive equity securities totaled 18,991,971 shares and 15,162,069 shares at December 31, 2013 and 2012, respectively.
	Comprehensive income – ASC 220, Comprehensive Income (formerly SFAS No. 130, Reporting Comprehensive Income) establishes standards for reporting comprehensive income (loss) and its components in a financial statement. Comprehensive income (loss) as defined includes all changes in equity (net assets) during a period from non-owner sources. The only source of other comprehensive income (loss) for the Company, which is excluded from net income (loss), is foreign currency translation adjustments.
	Stock-based compensation - The Company uses the fair value method of accounting prescribed by ASC 718, Compensation – Stock Compensation (formerly SFAS No. 123(R), Accounting for Stock-Based Compensation) for its employee stock option program. Under ASC 718, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the applicable vesting period of the stock award (generally up to three years).
	Research and development - Research and development costs are expensed as incurred. Research and development costs include payments to third parties that specifically relate to the Company’s products in clinical development, such as payments to contract research organizations, clinical investigators, clinical monitors, clinical related consultants and insurance premiums for clinical studies. In addition, employee costs (salaries, payroll taxes, benefits and travel) for employees of the regulatory affairs, clinical affairs, quality assurance, quality control, and research and development departments are classified as research and development costs.
	Recent pronouncements – There have been no recently issued accounting standards that are expected to have a material impact on our consolidated financial statements.

Note_2_Inventory

Note 2 - Inventory	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	(2)       Inventory
	Inventory consists of the following at December 31, 2013 and 2012:
		2013			2012
	Inventory - finished goods	$	254,864		$	306,706
	Inventory - parts		73,142			83,509
	Gross inventory		328,006			390,215
	Provision for losses and obsolescence		(82,000	)		(97,550	)
	Net inventory	$	246,006		$	292,665

Note_3_Property_and_Equipment

Note 3 - Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	(3)       Property and equipment
	Property and equipment consists of the following at December 31, 2013 and 2012:
		2013			2012
	Machines and equipment	$	233,793		$	233,793
	Office and computer equipment		171,404			179,349
	Software		41,872			41,872
	Furniture and fixtures		22,447			25,679
	Vehicles		-			22,531
	Other assets		2,446			2,446
	Total		471,962			505,670
	Accumulated depreciation		(458,695	)		(472,828	)
	Net property and equipment	$	13,267		$	32,842
	Depreciation expense was $19,575 and $20,375 for the years ended December 31, 2013 and 2012, respectively. The depreciation policies followed by the Company are described in Note (1).

Note_4_Intangible_Assets

Note 4 - Intangible Assets	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	(4)       Intangible assets
	Intangible assets consist of the following at December 31, 2013 and 2012:
		2013			2012
	Patents, at cost	$	3,502,135		$	3,502,135
	Less accumulated amortization		(2,581,866	)		(2,275,110	)
	Net intangible assets	$	920,269		$	1,227,025
	Amortization expense was $306,756 and $306,757 for the years ended December 31, 2013 and 2012, respectively. The amortization policies followed by the Company are described in Note (2).
	Amortization expense for the future years is summarized as follows:
	Years ending December 31,	Amount
	2014	$	306,756
	2015		306,756
	2016		306,757
	Total	$	920,269
	The weighted average amortization period for intangible assets is as follows:
					Weighted
					Average
					Period
		Amount			(Years)
	Patents	$	3,502,135			11.4

Note_5_Accrued_expenses

Note 5 - Accrued expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	(5)       Accrued expenses
	Accrued expenses consist of the following at December 31, 2013 and 2012:
		2013		2012
	Accrued executive severance	$	400,000	$	542,269
	Accrued clinical study expenses		188,927		-
	Accrued audit and tax preparation		91,000		102,600
	Accrued consultants		58,000		-
	Accrued board of director's fees		37,333		-
	Accrued legal professional fees		29,500		23,519
	Accrued other		58,812		53,528
		$	863,572	$	721,916
	On November 6, 2012, the Company entered into a Severance and Advisory Agreement (the “Severance Agreement”) with Christopher M. Cashman in connection with his resignation as President and Chief Executive Officer, and a director of the Company. Pursuant to the Severance Agreement, Mr. Cashman will receive, as severance along with other non-cash items, six months of his base salary payable over the following six month period and bonus payments of $100,000 upon each of four bonus payment events tied to the Company’s clinical trial plan for the dermaPACE device, or December 31, 2016, whichever occurs first. The accrued executive severance at December 31, 2013 represents the unpaid portion of the bonus payments and the balance at December 31, 2012 represents the unpaid portion of the base salary and bonus payments.

Note_6_Convertible_Promissory_

Note 6 - Convertible Promissory Note	12 Months Ended
	Dec. 31, 2013
Convertible Promissory Note [Abstract]	'
Convertible Promissory Note [Text Block]	'
	(6)       Convertible promissory note
	On December 23, 2013, the Company entered into a financing transaction for the sale of an 8% Convertible Promissory Note (the “$128,500 Convertible Note”) in the principal amount of $128,500, with gross proceeds of $125,000 to the Company after payment of related professional expenses. The offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Act and Rule 506 of Regulation D thereunder. The $128,500 Convertible Note was offered and sold to one accredited investor only.
	The $128,500 Convertible Note was issued pursuant to the terms of a purchase agreement among the Company and the accredited investor. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on September 26, 2014. The convertible note bears interest accruing at the rate of 8% per annum. The Company has the right to prepay the convertible note and accrued interest during the first one hundred eighty (180) days following the date of issuance. During that time, the amount of any prepayment during the first sixty (60) days is 120% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent thirty (30) days.
	The $128,500 Convertible Note is convertible, after the first one hundred eighty (180) days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 61% of the lowest three reported sale prices of the Company’s common stock for the 10 trading days immediately prior to the conversion date. The convertible note includes full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock.
	Subsequent to year end, the Company repaid the $128,500 Convertible Note in full, with accrued interest and the prepayment penalty, in March 2014 for $158,055.

Note_7_Promissory_Notes

Note 7 - Promissory Notes	12 Months Ended
	Dec. 31, 2013
Promissory Notes [Abstract]	'
Promissory Notes [Text Block]	'
	(7)       Promissory notes
	The Company issued short-term, unsecured promissory notes, in the aggregate principal amount of $360,000, between May 14, 2013 and July 9, 2013, to certain existing shareholders. The promissory notes accrue interest at a rate of 18% per annum and, together with all accrued and unpaid interest, are due and payable 179 days from their individual issuance date. In the event that the promissory notes are not paid in full within three business days of their respective maturity dates, then, from and after such maturity date and until payment in full, interest will accrue on the outstanding principal balance at a rate of 25% per annum. Joseph Chiarelli, the Company’s Chief Executive Officer, purchased promissory notes in the offering in the principal amount of $35,000. David N. Nemelka, the brother of John F. Nemelka, who is a member of the Company’s board of directors, purchased promissory notes in the offering in the principal amount of $100,000. On August 1, 2013, at the request of the promissory note holders, the Company repaid $325,000 of the original principal value of the notes in full, along with accrued interest of $10,664. At December 31, 2013, there was one promissory note outstanding in the original principal balance of $35,000 payable to Joseph Chiarelli.
	On December 11, 2013, the Company issued a promissory note in the principal amount of $50,000 to Dassity, Inc. The promissory note accrues interest at a rate of 8% per annum and, together with all accrued and unpaid interest, are due and payable 179 days from the issuance date. In the event that the promissory note is not paid in full within three business days of its respective maturity date, then, from and after such maturity date and until payment in full, interest will accrue on the outstanding principal balance at a rate of 16% per annum.

Note_8_Senior_Secured_Notes

Note 8 - Senior Secured Notes	12 Months Ended
	Dec. 31, 2013
Secured Convertible Promissory Notes [Abstract]	'
Secured Convertible Promissory Notes [Text Block]	'
	(8)       Senior secured notes
	During the period from November 2012 through March 8, 2013, the Company entered subscriptions payable for 18% senior secured convertible promissory notes (the “Senior Secured Notes”) from select accredited investors. The Company completed the offering and issued an aggregate $2,000,000 in Senior Secured Notes on March 8, 2013.
	The Senior Secured Notes had a six month term from the subscription date and the note holders could convert into Company common stock at anytime during the term at a conversion price of $0.20 per share – the market price at the time the subscription agreement was written. Upon the consummation of a qualified financing and/or technology license, as defined in the Senior Secured Note agreements, as amended, of $4,000,000 or more by the Company, the principal and interest on the Senior Secured Notes would automatically convert into Company common stock equal to the lower of (i) the Company common stock issued in the qualified financing and/or technology license, reduced by a discount of 20%, and (ii) $0.20 per share - the market price at the time the subscription agreement was written. The note holders (the “Holders”) would also receive, if any are issued, warrants or any other securities issued in a qualified financing and/or technology license on similar terms to the qualified financing and/or technology license. The Senior Secured Notes were secured by the tangible and intangible assets of the Company.
	On July 31, 2013, all of the Holders of the Senior Secured Notes voluntarily converted all of the outstanding principal and interest of the Senior Secured Notes into Company common stock. The aggregate outstanding amount of principal and interest on the Senior Secured Notes at July 31, 2013 of $2,186,906 was converted into 10,934,533 shares of restricted Company common stock at the conversion price of $0.20 per share - the market price at the time the subscription agreement was written - pursuant to the Senior Secured Note agreements. In return for the Holders’ voluntarily converting the outstanding Senior Secured Notes on or before July 31, 2013, the Company agreed to issue to the Holders warrants to purchase an aggregate total of 1,988,095 shares of Company common stock (the “Class H Warrants”). The Class H Warrants have an exercise price of $0.80 per share and are exercisable during the five-year period beginning on the date of issuance. In July 2013, the Company recorded a loss from extinguishment of debt of $1,073,572, which was the estimated fair value of the warrants issued to the Holders on the date of exchange calculated using the Black-Scholes pricing model using the following primary inputs of: (i) $0.60 closing stock price on the date of grant, (ii) the expected time the warrants will be outstanding of five-years, (iii) estimated discount rate of 1.38%, and (iv) expected volatility of 149% based on historical data from companies similar in size and value to the Company.
	Kevin A. Richardson, II, chairman of the board of directors of the Company, converted an aggregate balance of $64,500 of the Senior Secured Notes and received 322,500 shares of Company common stock and 58,635 Class H Warrants in the foregoing transaction.
	The conversion feature embedded in the Senior Secured Notes was accounted for as a derivative liability and resulted in the creation at issuance of a discount to the carrying amount of the debt in the amount of $2,000,000, which was amortized as additional interest expense using  the straight-line method over the term of the Senior Secured Notes (the Company determined that using the straight-line method of amortization did not yield a materially different amortization schedule than the effective interest method). The amount of the fair value of the embedded conversion feature in the Senior Secured Notes of $4,908,000, at the date of issuance, less the debt discount, totaled $2,908,000 and was recorded in the “loss on embedded conversion feature of Senior Secured Notes” in the accompanying consolidated statements of comprehensive loss; subsequent fair value adjustments of the embedded conversion feature of $534,187 are also included in this financial statement caption.
	Interest expense on the Senior Secured Notes, including amortization of the debt discount, totaled $2,178,390 and $8,516 for the years ended December 31, 2013 and 2012, respectively.

Note_9_Discontinued_Operations

Note 9 - Discontinued Operations	12 Months Ended
	Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	'
	(9)       Discontinued operations
	As of December 31, 2013 and 2012, the Company’s liabilities related to discontinued operations were as follows:
		2013		2012
	Accrued expenses	$	-	$	(655,061	)
	Liabilities of discontinued operations	$	-	$	(655,061	)
	In October 2008, the Company discontinued it Ossatron mobile service business and sold certain assets at that time to a minority shareholder of the Company. The Company estimated all potential liabilities related to the business at that time which totaled $655,061 and recorded them as liabilities related to discontinued operations on the consolidated balance sheet. The Company has continued to review the adequacy of the liability reserves in each fiscal year. As there has not been any activity or known potential claim related to these liabilities in the last five years, management has determined in accordance with Company policy, the liabilities should be eliminated in 2013. The Company recorded a non-cash gain on discontinued operations liabilities adjustment of $655,061 for the year ended December 31, 2013.

Note_10_Notes_Payable_Related_

Note 10 - Notes Payable, Related Parties	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	(10)     Notes payable, related parties
	The notes payable, related parties consist of the following at December 31, 2013 and 2012:
		2013		2012
	Notes payable, unsecured, payable to Healthtronics, Inc., a shareholder of the Company	$	5,372,743	$	5,372,743
	Less current portion		-		-
	Non-current portion	$	5,372,743	$	5,372,743
	The notes payable, related parties were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. on August 1, 2005. The notes payable, related parties bear interest at 6% per annum. Quarterly interest through June 30, 2010, was accrued and added to the principal balance. Interest is paid quarterly in arrears beginning September 30, 2010. All remaining unpaid accrued interest and principal is due August 1, 2015. Accrued interest currently payable totaled $163,729 and $81,864 at December 31, 2013 and 2012, respectively. Accrued interest not payable until August 1, 2015 totaled $1,372,743 at December 31, 2013 and 2012, and is included in the balance above.
	Maturities on notes payable, related parties are as follows:
	Years ending December 31,	Amount
	2014	$	-
	2015		5,372,743
	Total	$	5,372,743
	Interest expense on notes payable, related parties totaled $324,768 for each of the years ended December 31, 2013 and 2012.

Note_11_Income_Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	(11)     Income taxes
	The Company files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to United States federal and state and non-United States income tax examinations by tax authorities for years before 2007.
	Deferred income taxes are provided for temporary differences between the carrying amounts and tax basis of assets and liabilities. Deferred taxes are classified as current or noncurrent based on the financial statement classification of the related asset or liability giving rise to the temporary difference. For those deferred tax assets or liabilities (such as the tax effect of the net operating loss carryforwards) which do not relate to a financial statement asset or liability, the classification is based on the expected reversal date of the temporary difference.
	The income tax provision (benefit) for continuing operations consists of the following at December 31, 2013 and 2012:
		2013			2012
	Current:
	Federal	$	-		$	-
	State		-			-
	Foreign		-			-
			-			-
	Deferred:
	Federal		(2,116,355	)		(2,126,006	)
	State		(232,525	)		(227,883	)
	Foreign		9,144			12,556
	Change in valuation allowance		2,339,736			2,341,333
		$	-		$	-
	The income tax provision (benefit) amounts differ from the amounts computed by applying the United States federal statutory income tax rate of 35% to pretax income (loss) as a result of the following for the years ended December 31, 2013 and 2012:
		2013			2012
	Tax expense (benefit) at statutory rate	$	(4,184,174	)	$	(2,176,508	)
	Increase (reduction) in income taxes resulting from:
	State income taxes (benefit), net of federal benefit		(297,680	)		(159,432	)
	Non-deductible expenses on extinguishment of Senior Secured Notes		1,912,763			-
	Income from foreign subsidiaries		22,746			165,660
	Change in valuation allowance - United States		2,348,881			2,301,986
	Other		197,464			(131,706	)
	Income tax expense (benefit)	$	-		$	-
	The tax effects of temporary differences that give rise to the deferred tax assets at December 31, 2013 and 2012 are as follows:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	22,376,888		$	20,147,348
	Net operating loss carryforwards - foreign		139,529			148,674
	Excess of tax basis over book value of property and equipment		30,441			42,946
	Excess of tax basis over book value of intangible assets		435,541			431,513
	Stock-based compensation		3,396,235			3,097,308
	Accrued employee compensation		186,791			352,032
	Captialized equity costs		75,471			75,471
	Inventory reserve		30,943			36,811
			26,671,839			24,332,103
	Valuation allowance		(26,671,839	)		(24,332,103	)
	Net deferred tax assets	$	-		$	-
	The Company’s ability to use its net operating loss carryforwards could be limited and subject to annual limitations. In connection with future offerings, the Company may realize a “more than 50% change in ownership” which could further limit its ability to use its net operating loss carryforwards accumulated to date to reduce future taxable income and tax liabilities. Additionally, because United States tax laws limit the time during which net operating loss carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take advantage of all or portions of its net operating loss carryforwards for federal income tax purposes.
	The federal net operating loss carryforwards at December 31, 2013 will expire as follows:
	Years ending December 31,	Amount
	2025	$	1,376,740
	2026		7,291,084
	2027		12,280,771
	2028		6,922,963
	2029		4,816,700
	2030		7,667,557
	2031		8,816,976
	2032		4,768,716
	2033		5,357,637
	Total	$	59,299,144

Note_12_Equity_Transactions

Note 12 - Equity Transactions	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	(12)         Equity Transactions
	2013 Public Offering
	On July 25, 2013, the Company consummated a public offering (the “Public Offering”) of an aggregate of 3,006,818 units, with each unit consisting of one share of common stock and a warrant to purchase one-half share of a common stock (the “Class G Warrants”), resulting in warrants to purchase up to 1,503,409 shares of common stock.  The price per unit was $0.55 resulting in gross proceeds of $1,653,750. The Company received net proceeds, after payment of the placement agent’s fees, of $1,517,450. The units separated immediately and the common stock and warrants were issued separately. The Class G Warrants have an exercise price of $0.80 per share and are exercisable during the five-year period beginning on the date of issuance.
	2013 Private Placements
	In September, October and December 2013, the Company, in conjunction with offerings of securities (the “Private Placements”) of the Company, pursuant to an exemption from registration under the Act, issued 1,043,646 units (as described below) to certain “accredited investors,” as that term is defined in SEC Rule 501 under the Act, for an aggregate total purchase price of $626,188. Each unit was sold to the accredited investors at a purchase price of $0.60 per unit. Each “unit” in the Private Placements consists of; (i) one share of common stock and (ii) a five-year warrant to purchase one share of common stock, at an exercise price of $0.85 (the “Class I Warrants”). The Class I Warrants are callable by the Company if the average share price of common stock of the Company is at or above $1.40 for a twenty day period.
	Kevin A. Richardson II, who is the chairman of the board of directors of the Company, and Joseph Chiarelli, who is the Chief Executive Officer of the Company, and Michael M. Nemelka, who is the brother of John F. Nemelka, a member of the board of directors of the Company, purchased units in the Private Placements.
	Consulting Agreements
	In February 2013, the Company entered into certain consulting agreements for which a portion of the fee for the services performed was paid with Company common stock. In August and September 2013, the Company entered into two additional consulting agreements for which a portion of the fee for the services performed was paid with Company common stock. The Company issued 1,583,315 shares of common stock under these agreements for the year ended December 31, 2013. The fair value of the common stock of $1,014,267, based upon the closing market price of the Company’s common stock at the dates the common stock was issued, was recorded as a non-cash general and administrative expense for the year ended December 31, 2013.
	Preferred Stock
	The Company’s preferred stock may have such rights, preferences and designations and may be issued in such series as determined by the board of directors. No shares were issued and outstanding at December 31, 2013 and 2012.

Note_13_Warrants

Note 13 - Warrants	12 Months Ended
	Dec. 31, 2013
Warrants [Abstract]	'
Warrants [Text Block]	'
	(13)        Warrants
	A summary of warrants as of December 31, 2013 and 2012, and the changes during the years ended December 31, 2013 and 2012, is presented as follows:
		Class A		Class B		Class D			Class E		Class F			Class G		Class H		Class I
		Warrants		Warrants		Warrants			Warrants		Warrants			Warrants		Warrants		Warrants
	Outstanding as of December 31, 2011		1,106,627		1,106,627		4,235,160			3,576,737		-			-		-		-
	Issued		-		-		-			-		-			-		-		-
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		(2,284,993	)		-		-			-		-		-
	Outstanding as of December 31, 2012		1,106,627		1,106,627		1,950,167			3,576,737		-			-		-		-
	Issued		-		-		-			-		2,000,000			1,503,409		1,988,095		1,043,646
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		(1,950,167	)		-		(1,700,000	)		-		-		-
	Outstanding as of December 31, 2013		1,106,627		1,106,627		-			3,576,737		300,000			1,503,409		1,988,095		1,043,646
	A summary of the warrant exercise price per share and expiration date is presented as follows:
		Class A		Class B		Class D			Class E		Class F			Class G		Class H		Class I
		Warrants		Warrants		Warrants			Warrants		Warrants			Warrants		Warrants		Warrants
	Exercise price/share	$	4	$	8	$	2		$	4	$	0.35		$	0.8	$	0.8	$	0.85
	Expiration Date	September		September		January			April		February			July		July		Sept - Dec
		2014		2014		2013			2016		2018			2018		2018		2018
	The exercise price and the number of shares covered by the warrants will be adjusted if the Company has a stock split, if there is a recapitalization of the Company’s common stock, or if the Company consolidates with or merges into another company.
	In February 2013, the Company issued 2,000,000 warrants to a consultant to purchase the Company’s common stock at $0.35 per share (the “Class F Warrants”). The five year Class F Warrants vest 300,000 on the date of grant and 1,700,000 upon the completion of a $5,000,000, or greater, capital raise on or prior to June 8, 2013. A capital raise was not completed for the requisite amount and the 1,700,000 Class F Warrants expired by their terms. The Company recorded the underlying cost of the 300,000 Class F Warrants as a cost of the Public Offering.

Note_14_Commitments_and_Contin

Note 14 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	(14)        Commitments and contingencies
	Subscription agreement
	On November 27, 2012, the Company and David N. Nemelka (the “Subscriber”), the brother of John F. Nemelka, a member of the Company’s board of directors, entered into a subscription agreement (the “Subscription Agreement”) whereby the Subscriber has agreed to purchase from the Company, and the Company has agreed to sell and issue, a total of 4,000,000 shares of the Company’s unregistered common stock at a purchase price equal to $0.25 per share, for an aggregate sales price of $1,000,000 (the “Purchase Price”). The shares are subject to piggy-back registration rights if the Company files a registration statement for an offering of securities.
	The Purchase Price shall be payable to the Company as follows: (i) $50,000 on or before January 31, 2013; (ii) $50,000 on or before February 15, 2013; and (iii) the balance of $900,000 on or before May 27, 2014 (the “Outside Due Date”). The Subscriber may make payments of the Purchase Price at his discretion in minimum installments of $100,000 each, until the Outside Due Date.
	In the event that at any time after February 15, 2013, the Company’s total available cash should be less than $100,000, the Subscriber shall, upon demand of the Company, pay to the Company $100,000 of the then outstanding balance of the Purchase Price, which payment shall be due within thirty (30) days of the demand. There is no limit on the number of demands that the Company may make pursuant to this provision of the Subscription Agreement, provided, however, that in no event shall the Company provide more than one notice of demand for payment in any thirty (30) day period.
	As of December 31, 2013 and 2012, respectively, the Subscriber had paid the Company $100,000 and $25,000 and was issued 400,000 and 100,000 shares of unregistered common stock of the Company. The Company will record the additional $900,000 and issue the corresponding 3,600,000 shares of common stock in the periods in which the Purchase Price is received.
	Operating Leases
	The Company leases office and warehouse space. Rent expense for the years ended December 31, 2013 and 2012, was $124,286 and $298,452, respectively. Minimum future lease payments under non-cancellable operating leases consist of the following:
	Year ending December 31,	Amount
	2014	$	105,643
	2015		90,225
	Total	$	195,868
	Capital Leases
	The Company leases certain office equipment under an agreement classified as a capital lease. The leased assets serve as security for the lease. The accumulated depreciation of such equipment at December 31, 2013 and 2012 totaled $11,318 and $6,468, respectively. The net book value of such equipment at December 31, 2013 and 2012 totaled $3,234 and $8,085, respectively.
	The future commitments as of December 31, 2013 under this capital lease agreement are as follows:
	Year ending December 31,	Principal		Interest		Total
	2014	$	3,951	$	125	$	4,076
		$	3,951	$	125	$	4,076
	Litigation
	The Company is involved in various legal matters that have arisen in the ordinary course of business. While the ultimate outcome of these matters is not presently determinable, it is the opinion of management that the resolution will not have a material adverse effect on the financial position or results of operations of the Company.

Note_15_401k_Plan

Note 15 - 401(k) Plan	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]	'
	(15)        401(k) plan
	The Company sponsors a 401(k) plan that covers all employees who meet the eligibility requirements. The Company matched 50% of employee contributions up to 6% of their compensation effective until January 31, 2012. Effective February 1, 2012, the Company amended the 401(k) plan to make the Company matching contribution discretionary and discontinued the Company match. The Company contributed $0 and $9,664 to the plan for the years ended December 31, 2013 and 2012, respectively.

Note_16_Stockbased_Compensatio

Note 16 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	(16)        Stock-based compensation
	On November 1, 2010, the Company approved the Amended and Restated 2006 Stock Incentive Plan of SANUWAVE Health, Inc. effective as of January 1, 2010 (the “Stock Incentive Plan”). The Stock Incentive Plan permits grants of awards to selected employees, directors and advisors of the Company in the form of restricted stock or options to purchase shares of common stock. Options granted may include non-statutory options as well as qualified incentive stock options. The Stock Incentive Plan is currently administered by the board of directors of the Company. The Stock Incentive Plan gives broad powers to the board of directors of the Company to administer and interpret the particular form and conditions of each option. The stock options granted under the Stock Incentive Plan are non-statutory options which generally vest over a period of up to three years and have a ten year term. The options are granted at an exercise price determined by the board of directors of the Company to be the fair market value of the common stock on the date of the grant. At December 31, 2012, the Stock Incentive Plan reserved 5,000,000 shares of common stock for grant. On February 21, 2013, the Stock Incentive Plan was amended to reserve a total of 8,500,000 shares of common stock for grant.
	On September 3, 2013, the Company granted 100,000 options to the new member of the board of directors at an exercise price of $0.65 per share. The options vested at the date of grant and have a ten year term. Using the Black-Scholes option pricing model, management has determined that the options had a weighted average fair value per share of $0.60 resulting in total compensation of $60,000. Compensation cost was recognized at grant date.
	On February 21, 2013, the Company, by mutual agreement with all the active employees and directors of the Company, cancelled options granted to the active employees in the year ended December 31, 2011 and prior which totaled 1,113,644 shares of common stock at an average exercise price of $2.92. In exchange for these options, the active employees and directors received new options to purchase 2,243,644 shares of common stock at an exercise price of $0.35 per share. Using the Black-Scholes option pricing model, management has determined that the options at the grant date, net of the value of the cancelled options as of the date of cancellation, had an average fair value per share of $0.223 resulting in total compensation of $499,621. Compensation cost will be recognized over the requisite service period.
	On February 21, 2013, the Company granted two members of the Company’s Medical Advisory Board each options to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.35 per share in place of an annual cash consulting fee for calendar year 2013. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.64 resulting in compensation expense of $64,000. Compensation cost will be recognized over the calendar year 2013.
	On February 25, 2013, Joseph Chiarelli joined the Company to serve as the Chief Executive Officer and a director of the Company. Mr. Chiarelli was granted options to purchase 2,250,000 shares of the Company’s common stock at an exercise price of $0.35 per share. The options vest and become exercisable in five installments as follows: (i) 375,000 vested at grant; (ii) 375,000 vest upon the Company completing a financing resulting in gross proceeds to the Company of no less than $5,000,000 at a price per share of not less than $0.35; (iii) 375,000 upon the execution by the Company of a license or distribution agreement from which the Company is entitled to receive gross proceeds of no less than $1,000,000 and the Company has received payments of at least $250,000; (iv) 375,000 vest upon receipt by the Company of FDA approval for the use of dermaPACE; and (v) 750,000 vest in the event the Company achieves the milestones (i), (ii), (iii) and (iv) above during the initial two year term and the agreement is not extended by the Company. Using the Black-Scholes option pricing model, management has determined that the options had an average fair value per share of $0.207 resulting in total compensation of $465,000. Compensation cost will be recognized over the requisite service period.
	As discussed in Note (5), on November 6, 2012, the Company entered into a Severance Agreement with Christopher M. Cashman in connection with his resignation as President and Chief Executive Officer, and a director of the Company. Pursuant to the Severance Agreement, Mr. Cashman received (a) a grant of 1,000,000 options to acquire shares of common stock at an exercise price of $0.21 per share with 600,000 of the options vested upon the execution of the Severance Agreement and the remaining 400,000 options vesting in increments of 100,000 upon events tied to the Company’s clinical trial plan for the dermaPACE device, or December 31, 2016, whichever occurs first, (b) a grant of 50,000 options to acquire shares of common stock at an exercise price of $0.21 per share as consideration for the provision of twelve months of advisory services and (c) the full vesting of all other outstanding and unvested options. Using the Black-Scholes option pricing model, management has determined that the options granted in November 2012 had a fair value per share of $0.15 resulting in total compensation of $160,500. Compensation cost will be recognized over the requisite vesting period.
	On March 8, 2012, the Company granted two members of the Company’s Medical Advisory Board each options to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.44 per share in place of an annual cash consulting fee. Using the Black-Scholes option pricing model, management has determined that the options granted in March 2012 had a fair value per share of $0.27 resulting in total compensation of $27,250. Compensation cost was recognized over the calendar year 2012.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the years ended December 31, 2013 and 2012:
		2013			2012
	Weighted average expected life in years		4.3			5.2
	Weighted average risk free interest rate		0.73	%		0.81	%
	Weighted average volatility		149.85	%		97.83	%
	Forfeiture rate		0	%		0	%
	Expected dividend yield		0	%		0	%
	The expected life of options granted represent the period of time that options granted are expected to be outstanding and are derived from the contractual terms of the options granted. The risk-free rate for periods within the contractual life of the option  is based on the U.S. Treasury yield curve in effect at the time of the grant. Since there is a limited trading history for our common stock, the expected volatility is based on historical data from companies similar in size and value to us. We estimate pre-vesting forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The expected dividend yield is based on our historical dividend experience, however, since our inception, we have not declared dividends. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. Ultimately, the total expense recognized over the vesting period will equal the fair value of the awards that actually vest.
	For the years ended December 31, 2013 and 2012, the Company recognized $792,160 and $1,391,316, respectively, as compensation cost related to options granted. The remaining compensation cost will be recognized as follows:
		Unrecognized
		Compensation
	Years ending December 31,	Cost
	2014	$	214,106
	2015		35,151
	Total	$	249,257
	A summary of option activity as of December 31, 2013 and 2012, and the changes during the years ended December 31, 2013 and 2012, is presented as follows:
					Weighted
					Average
					Exercise Price
		Options			per share
	Outstanding at December 31, 2011		4,365,546		$	2.82
	Granted		1,150,000		$	0.23
	Exercised		-		$	-
	Forfeited or expired		(286,216	)	$	2.85
	Outstanding at December 31, 2012		5,229,330		$	2.25
	Granted		4,693,644		$	0.36
	Exercised		(108,334	)	$	0.35
	Cancelled		(1,113,644	)	$	2.92
	Forfeited or expired		(334,166	)	$	1.15
	Outstanding at December 31, 2013		8,366,830		$	1.17
	Vested and exercisable at December 31, 2013		5,112,738		$	1.69
	The range of exercise prices for options was $0.21 to $2.92 for options outstanding at December 31, 2013, and $0.44 to $4.05 for option outstanding at December 31, 2012. The aggregate intrinsic value for exercised options was $92,030 for the year ended December 31, 2013. The aggregate intrinsic value for outstanding options was $1,271,540 and $0 at December 31, 2013 and 2012, respectively. The aggregate intrinsic value for all vested and exercisable options was $574,181 and $0 at December 31, 2013 and 2012, respectively.
	The weighted average remaining contractual term for outstanding exercisable stock options is 6.96 years as of December 31, 2013 and 6.63 years as of December 31, 2012.
	A summary of the Company’s nonvested options as of December 31, 2013 and 2012, and changes during the years ended December 31, 2013 and 2012, is presented as follows:
					Weighted
					Average
					Exercise Price
		Options			per share
	Outstanding at December 31, 2011		1,314,722		$	2.48
	Granted		1,150,000		$	0.23
	Vested		(1,901,722	)	$	1.52
	Forfeited or expired		(54,250	)	$	3.41
	Outstanding at December 31, 2012		508,750		$	0.66
	Granted		4,693,644		$	0.36
	Vested		(1,667,886	)	$	0.39
	Cancelled		(43,750	)	$	2.87
	Forfeited or expired		(236,666	)	$	0.5
	Outstanding at December 31, 2013		3,254,092		$	0.35

Note_17_Changes_in_Other_Compr

Note 17 - Changes in Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	(17)        Changes in other comprehensive loss
	A summary of the amounts recognized in other comprehensive loss as of December 31, 2013 and 2012, and changes during the year ended December 31, 2013, is presented as follows:
		Currency
		Translations			Total
	Balance, at December 31, 2012	$	13,116		$	13,116
	Other comprehensive loss before reclassifications		(6,428	)		(6,428	)
	Amounts reclassified from AOCI		-			-
	Net change in other comprehensive loss		(6,428	)		(6,428	)
	Balance, at December 31, 2013	$	6,688		$	6,688

Note_18_Segment_and_Geographic

Note 18 - Segment and Geographic Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	(18)        Segment and geographic information
	The Company has one line of business with revenue being generated from sales in Europe, Asia and Asia/Pacific. All significant expenses are generated in the United States. All significant assets are located in the United States.

Note_19_Subsequent_Events

Note 19 - Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	(19)        Subsequent events
	The Company has evaluated subsequent events through the date of issuance of the consolidated financial statements.
	2014 Private Offering
	On March 17, 2014, in conjunction with a private offering of securities (the “2014 Private Offering”) with institutional and select accredited investors, the Company issued an aggregate total of 6,210,000 shares of common stock and 6,175 shares of the preferred stock (the “Series A Convertible Preferred Stock”) for an aggregate total purchase price of $9,280,000. Each share of Series A Convertible Preferred Stock is convertible into 2,000 shares of common stock at the option of the holder.
	The Company, in connection with the 2014 Private Offering, issued to the investors an aggregate total of 23,200,000 warrants (the “Series A Warrants”) to purchase shares of common stock at an exercise price of $0.50 per share. Each Series A Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after five years.
	In addition, the Company, in connection with the 2014 Private Offering, issued to the investors an aggregate total of 13,920,000 warrants (the “Series B Warrants”) to purchase shares of common stock at an exercise price of $1.50 per share. Each Series B Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after one year.
	Pursuant to the terms of a Registration Rights Agreement that the Company entered with the investors in connection with the 2014 Private Offering, the Company is required to file a registration statement in April 2014 that covers the shares of common stock and the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and exercise of the Series A Warrants and Series B Warrants. The failure on the part of the Company to satisfy certain deadlines described in the Registration Rights Agreement may subject the Company to payment of certain monetary penalties.
	Kevin A. Richardson, II, chairman of the board of directors of the Company; Joseph Chiarelli, Chief Executive Officer of the Company and a member of the Company’s board of directors; and, Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, were purchasers in the 2014 Private Offering of $50,000, $40,000 and $50,000, respectively.
	18% Convertible Promissory Notes
	During the period January 24, 2014 through March 7, 2014, the Company entered into subscriptions payable for 18% convertible promissory notes, as amended, (the “18% Convertible Promissory Notes”) from selected accredited investors. Up to $1,000,000 aggregate principal amount of 18% Convertible Promissory Notes were offered by the Company. The Company completed the offering and issued an aggregate $815,000 in convertible notes in March 2014. Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, purchased $110,000 of the convertible notes.
	The 18% Convertible Promissory Notes have a nine (9) month term from the subscription date and the note holders can convert into Company common stock at anytime during the term at $0.55 per share. Upon the consummation of a qualified financing, as defined in the convertible note agreements, of $1,000,000 or more by the Company, the principal and interest on the 18% Convertible Promissory Notes will convert into Company common stock equal to the lower of (i) the Company common stock issued in the qualified financing, and (ii) $0.55 per share. The note holders will also receive, if any are issued, warrants or any other security issued in a qualified financing on similar terms to the qualified financing. The 18% Convertible Promissory Notes are unsecured.
	On March 17, 2014, in conjunction with the 2014 Private Offering, the 18% Convertible Promissory Notes were automatically converted under the same terms as the Offering. The 2014 Private Offering was a qualified financing as defined in the 18% Convertible Promissory Notes. The unpaid principal and interest balance, which in the aggregate totaled $822,168, were converted into 1,644,337 shares of common stock. In addition, under the same terms as in the 2014 Private Offering, the Company issued to the note holders an aggregate total of 2,055,421 Series A Warrants and 1,233,252 Series B Warrants.
	$278,500 Convertible Promissory Note and Warrants
	On February 10, 2014, the Company entered into a financing transaction for the sale of an 8% Convertible Promissory Note (the “$278,500 Convertible Note”) and warrants (the “Class J Warrants”) in the principal amount of $278,500, with gross proceeds of $250,000 to the Company after payment of a 10% original issue discount and related professional expenses. The offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Act and Rule 506 of Regulation D thereunder. The Company did not utilize any form of general solicitation or general advertising in connection with the offering. The $278,500 Convertible Note was offered and sold to one accredited investor.
	The $278,500 Convertible Note and Class J Warrants were issued pursuant to the terms of a purchase agreement among the Company and the Investor. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on August 11, 2014. The convertible note bears interest accruing at the rate of 8% per annum and includes a 10%, or $25,000, original issuance discount. The Company has the right to prepay the convertible note and accrued interest during the first one hundred eighty (180) days following the date of issuance. During that time, the amount of any prepayment during the first sixty (60) days is 120% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent thirty (30) days.
	The $278,500 Convertible Note is convertible, after the first one hundred eighty (180) days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of the lower of 75% of the lowest reported sale price of the Company’s common stock for the 20 trading days immediately prior to (i) the closing date of the financing, or (ii) 75% of the lowest reported sale price for the twenty (20) days prior the conversion date of the convertible note. The convertible note includes full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock.
	The Class J Warrants entitle the investor to purchase, in the aggregate, 629,378 shares of the Company’s common stock. The Warrants will not be exercisable until the six (6) month anniversary of the closing date (August 10, 2014) and will expire five (5) years from the closing date. The Class J Warrants are initially exercisable at an exercise price equal to $0.4425, subject to certain adjustments. The Class J Warrants may be exercised for cash or on a cashless basis. The exercise price of the Warrants is subject to adjustment for stock splits, combinations or similar events, and, in this event, the number of shares issuable upon the exercise of the Warrant will also be adjusted so that the aggregate exercise price shall be the same immediately before and immediately after the adjustment. In addition, the exercise price is also subject to a “full ratchet” anti-dilution adjustment where if the Company issues or is deemed to have issued securities at a price lower than the then applicable exercise price.
	Subsequent to year end, the Company repaid the $278,500 Convertible Note in full, with accrued interest and the prepayment penalty, in March 2014.
	$78,500 Convertible Promissory Note
	On February 18, 2014, the Company entered into a second tranche of financing with the investor for the $128,500 Convertible Promissory Note for the sale of 8% Convertible Promissory Note (the “$78,500 Convertible Note”) under the same terms as the first tranche in the principal amount of $78,500, with gross proceeds of $75,000 to the Company after payment of related professional expenses. The offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Act and Rule 506 of Regulation D thereunder.
	The $78,500 Convertible Note was issued pursuant to the terms of a purchase agreement among the Company and the accredited investor. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on November 20, 2014. The convertible note bears interest accruing at the rate of 8% per annum. The Company has the right to prepay the convertible note and accrued interest during the first one hundred eighty (180) days following the date of issuance. During that time, the amount of any prepayment during the first sixty (60) days is 120% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent thirty (30) days.
	The $78,500 Convertible Note is convertible, after the first one hundred eighty (180) days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 61% of the lowest three reported sale prices of the Company’s common stock for the 10 trading days immediately prior to the conversion date. The convertible note includes full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock.
	Subsequent to year end, the Company repaid the $78,500 Convertible Note in full, with accrued interest and the prepayment penalty, in March 2014.
	Consulting Agreements
	In February 2014, the Company renewed one consulting contract and entered into three additional consulting agreements for which a portion of the fee for the services performed was paid with Company common stock. The Company issued 835,000 shares of common stock under these agreements in February and March, 2014. The fair value of the common stock of issued to the consultants, based upon the closing market price of the Company’s common stock at the dates the common stock was issued, was recorded as a non-cash general and administrative expense for the three months ended March 31, 2014.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign currency translation - The functional currencies of the Company’s foreign operations are the local currencies. The financial statements of the Company’s foreign subsidiary have been translated into United States dollars in accordance with ASC 830, Foreign Currency Matters (formerly SFAS No. 52, Foreign Currency Translation.) All balance sheet accounts have been translated using the exchange rates in effect at the balance sheet date. Income statement amounts have been translated using the average exchange rate for the year. Translation adjustments are reported in other comprehensive income in the consolidated statements of comprehensive loss and as cumulative translation adjustments as a separate component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders’ deficit.
Consolidation, Policy [Policy Text Block]	'
	Principles of consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	'
	Estimates – These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America. Because a precise determination of assets and liabilities, and correspondingly revenue and expenses, depend on future events, the preparation of consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These consolidated financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein. Significant estimates include the recording of allowances for doubtful accounts, estimated reserves for inventory, estimated useful life of property and equipment, accrued expenses, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation and the estimated fair value of intangible assets.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and cash equivalents - For purposes of the consolidated financial statements, liquid instruments with an original maturity of 90 days or less are considered cash and cash equivalents. The Company maintains its cash in bank accounts which may exceed federally insured limits.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of credit risk and limited suppliers - Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. Two distributors accounted for 28% and 22% of revenue for the year ended December 31, 2013, and 20% and 29% of revenue for the year ended December 31, 2012. The two distributors accounted for 10% and 11% of accounts receivable at December 31, 2013, and 6% and 35% of accounts receivable at December 31, 2012.
	We depend on suppliers for product component materials and other components that are subject to stringent regulatory requirements. We currently purchase most of our product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may be difficult to arrange a replacement supplier because certain of these materials may only be available from one or a limited number of sources. In addition, establishing additional or replacement suppliers for these materials may take a substantial period of time, as certain of these suppliers must be approved by regulatory authorities.
Receivables, Policy [Policy Text Block]	'
	Accounts receivable - Accounts receivable are stated at the amount management expects to collect from outstanding balances. Management provides for probable uncollectible amounts through a charge to earnings based on its assessment of the current status of individual accounts. Receivables are generally considered past due if greater than 60 days old. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts.
Inventory, Policy [Policy Text Block]	'
	Inventory - Inventory consists of finished medical equipment and parts and is stated at the lower of cost or market, which is valued using the first in, first out (“FIFO”) method. Market is based upon realizable value less allowance for selling and distribution expenses. The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Depreciation of property and equipment - The straight-line method of depreciation is used for computing depreciation on property and equipment. Depreciation is based on estimated useful lives as follows: machines and equipment, 3 years; office and computer equipment, 3 years; furniture and fixtures, 3 years; vehicles, 3 years; and software, 2 years.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Intangible assets - Intangible assets subject to amortization consist of patents which are recorded at cost. Patents are amortized on a straight-line basis over the average life of 11.4 years. The Company regularly reviews intangible assets to determine if facts and circumstances indicate that the useful life is shorter than the Company originally estimated or that the carrying amount of the assets may not be recoverable. Factors the Company considers important and could trigger an impairment review include the following:
		●	Significant delays or obstacles encountered in the dermaPACE device clinical trial and PMA application;
		●	Significant changes in the manner in which the Company uses its assets or significant changes in the Company’s overall business strategy; and
		●	Significant underperformance of the Company’s assets relative to future operating results.
	If such facts and circumstances exist, the Company assesses the recoverability of the intangible assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds its fair value.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair value of financial instruments - The book values of accounts receivable, accounts payable, and other financial instruments approximate their fair values, principally because of the  short-term maturities of these instruments.
	The Company has adopted ASC 820-10, Fair Value Measurements (formerly SFAS No. 157), which defines fair value, establishes a framework for measuring fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements.
	The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and  requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:
	Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for  identical assets and liabilities;
	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for  the asset or liability, either directly or indirectly; and
	Level 3 - Unobservable inputs that are not corroborated by market data, therefore  requiring the Company to develop its own assumptions.
	The Company’s notes payable, related parties consist of $5,372,743 of principal at December 31, 2013 and 2012. Interest accrues on the notes at a rate of six percent (6%) per annum. The fair value was determined using estimated future cash flows discounted at current rates, which is a Level 3 measurement. The estimated fair value of the Company’s notes payable, related parties was $4,653,780 and $4,545,620 at December 31, 2013 and 2012, respectively.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Impairment of long-lived assets – The Company reviews long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts of the assets may not be recoverable. An impairment loss is recognized only if the carrying amount of the asset is not recoverable and exceeds its fair value. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the asset’s carrying value is not recoverable, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds its fair value. The Company determines fair value by using a combination of comparable market values and discounted cash flows, as appropriate.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition - Sales of medical devices, including related applicators and applicator kits, are recognized when shipped to the customer. Shipments under agreements with distributors are invoiced at a fixed price, are not subject to return, and payment for these shipments is not contingent on sales by the distributor. The Company recognizes revenue on shipments to distributors in the same manner as with other customers. Fees from services performed are recognized when the service is performed.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Shipping and handling costs - Shipping charges billed to customers are included in revenue. Shipping and handling costs have been recorded in cost of revenue.
Income Tax, Policy [Policy Text Block]	'
	Income taxes - Income taxes are accounted for utilizing the asset and liability method prescribed by the provisions of ASC 740, Income Taxes (formerly SFAS No. 109, Accounting for Income Taxes). Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided for the deferred tax assets, including loss carryforwards, when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
	A provision of ASC 740, Income Taxes (formerly FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48)) specifies the way public companies are to account for uncertainties in income tax reporting, and prescribes a methodology for recognizing, reversing, and measuring the tax benefits of a tax position taken, or expected to be taken, in a tax return. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions would “more-likely-than-not” be sustained if challenged by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold would be recorded as a tax benefit or expense in the current year.
	The Company will recognize in income tax expense interest and penalties related to income tax matters. For the years ended December 31, 2013 and 2012, the Company did not have any amounts recorded for interest and penalties.
Earnings Per Share, Policy [Policy Text Block]	'
	Loss per share - The Company calculates net income (loss) per share in accordance with ASC 260, Earnings Per Share (formerly SFAS No. 128, Earnings Per Share).  Under the provisions of ASC 260, basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of shares of common stock outstanding for the period.  Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents then outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share. As a result of the net loss for the years ended December 31, 2013 and 2012, respectively, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. The anti-dilutive equity securities totaled 18,991,971 shares and 15,162,069 shares at December 31, 2013 and 2012, respectively.
Comprehensive Income, Policy [Policy Text Block]	'
	Comprehensive income – ASC 220, Comprehensive Income (formerly SFAS No. 130, Reporting Comprehensive Income) establishes standards for reporting comprehensive income (loss) and its components in a financial statement. Comprehensive income (loss) as defined includes all changes in equity (net assets) during a period from non-owner sources. The only source of other comprehensive income (loss) for the Company, which is excluded from net income (loss), is foreign currency translation adjustments.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-based compensation - The Company uses the fair value method of accounting prescribed by ASC 718, Compensation – Stock Compensation (formerly SFAS No. 123(R), Accounting for Stock-Based Compensation) for its employee stock option program. Under ASC 718, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the applicable vesting period of the stock award (generally up to three years).
Research and Development Expense, Policy [Policy Text Block]	'
	Research and development - Research and development costs are expensed as incurred. Research and development costs include payments to third parties that specifically relate to the Company’s products in clinical development, such as payments to contract research organizations, clinical investigators, clinical monitors, clinical related consultants and insurance premiums for clinical studies. In addition, employee costs (salaries, payroll taxes, benefits and travel) for employees of the regulatory affairs, clinical affairs, quality assurance, quality control, and research and development departments are classified as research and development costs.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent pronouncements – There have been no recently issued accounting standards that are expected to have a material impact on our consolidated financial statements.

Note_2_Inventory_Tables

Note 2 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		2013			2012
	Inventory - finished goods	$	254,864		$	306,706
	Inventory - parts		73,142			83,509
	Gross inventory		328,006			390,215
	Provision for losses and obsolescence		(82,000	)		(97,550	)
	Net inventory	$	246,006		$	292,665

Note_3_Property_and_Equipment_

Note 3 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		2013			2012
	Machines and equipment	$	233,793		$	233,793
	Office and computer equipment		171,404			179,349
	Software		41,872			41,872
	Furniture and fixtures		22,447			25,679
	Vehicles		-			22,531
	Other assets		2,446			2,446
	Total		471,962			505,670
	Accumulated depreciation		(458,695	)		(472,828	)
	Net property and equipment	$	13,267		$	32,842

Note_4_Intangible_Assets_Table

Note 4 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		2013			2012
	Patents, at cost	$	3,502,135		$	3,502,135
	Less accumulated amortization		(2,581,866	)		(2,275,110	)
	Net intangible assets	$	920,269		$	1,227,025
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Years ending December 31,	Amount
	2014	$	306,756
	2015		306,756
	2016		306,757
	Total	$	920,269
Schedule of Amortization Period for Intangible Assets [Table Text Block]	'
					Weighted
					Average
					Period
		Amount			(Years)
	Patents	$	3,502,135			11.4

Note_5_Accrued_expenses_Tables

Note 5 - Accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		2013		2012
	Accrued executive severance	$	400,000	$	542,269
	Accrued clinical study expenses		188,927		-
	Accrued audit and tax preparation		91,000		102,600
	Accrued consultants		58,000		-
	Accrued board of director's fees		37,333		-
	Accrued legal professional fees		29,500		23,519
	Accrued other		58,812		53,528
		$	863,572	$	721,916

Note_9_Discontinued_Operations1

Note 9 - Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
		2013		2012
	Accrued expenses	$	-	$	(655,061	)
	Liabilities of discontinued operations	$	-	$	(655,061	)

Note_10_Notes_Payable_Related_1

Note 10 - Notes Payable, Related Parties (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		2013		2012
	Notes payable, unsecured, payable to Healthtronics, Inc., a shareholder of the Company	$	5,372,743	$	5,372,743
	Less current portion		-		-
	Non-current portion	$	5,372,743	$	5,372,743
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	Years ending December 31,	Amount
	2014	$	-
	2015		5,372,743
	Total	$	5,372,743

Note_11_Income_Taxes_Tables

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
		2013			2012
	Current:
	Federal	$	-		$	-
	State		-			-
	Foreign		-			-
			-			-
	Deferred:
	Federal		(2,116,355	)		(2,126,006	)
	State		(232,525	)		(227,883	)
	Foreign		9,144			12,556
	Change in valuation allowance		2,339,736			2,341,333
		$	-		$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		2013			2012
	Tax expense (benefit) at statutory rate	$	(4,184,174	)	$	(2,176,508	)
	Increase (reduction) in income taxes resulting from:
	State income taxes (benefit), net of federal benefit		(297,680	)		(159,432	)
	Non-deductible expenses on extinguishment of Senior Secured Notes		1,912,763			-
	Income from foreign subsidiaries		22,746			165,660
	Change in valuation allowance - United States		2,348,881			2,301,986
	Other		197,464			(131,706	)
	Income tax expense (benefit)	$	-		$	-
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	22,376,888		$	20,147,348
	Net operating loss carryforwards - foreign		139,529			148,674
	Excess of tax basis over book value of property and equipment		30,441			42,946
	Excess of tax basis over book value of intangible assets		435,541			431,513
	Stock-based compensation		3,396,235			3,097,308
	Accrued employee compensation		186,791			352,032
	Captialized equity costs		75,471			75,471
	Inventory reserve		30,943			36,811
			26,671,839			24,332,103
	Valuation allowance		(26,671,839	)		(24,332,103	)
	Net deferred tax assets	$	-		$	-
Summary of Operating Loss Carryforwards [Table Text Block]	'
	Years ending December 31,	Amount
	2025	$	1,376,740
	2026		7,291,084
	2027		12,280,771
	2028		6,922,963
	2029		4,816,700
	2030		7,667,557
	2031		8,816,976
	2032		4,768,716
	2033		5,357,637
	Total	$	59,299,144

Note_13_Warrants_Tables

Note 13 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Warrants [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Class A		Class B		Class D			Class E		Class F			Class G		Class H		Class I
		Warrants		Warrants		Warrants			Warrants		Warrants			Warrants		Warrants		Warrants
	Outstanding as of December 31, 2011		1,106,627		1,106,627		4,235,160			3,576,737		-			-		-		-
	Issued		-		-		-			-		-			-		-		-
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		(2,284,993	)		-		-			-		-		-
	Outstanding as of December 31, 2012		1,106,627		1,106,627		1,950,167			3,576,737		-			-		-		-
	Issued		-		-		-			-		2,000,000			1,503,409		1,988,095		1,043,646
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		(1,950,167	)		-		(1,700,000	)		-		-		-
	Outstanding as of December 31, 2013		1,106,627		1,106,627		-			3,576,737		300,000			1,503,409		1,988,095		1,043,646
Schedule of Warrant Exercise Price and Expiration Date [Table Text Block]	'
		Class A		Class B		Class D			Class E		Class F			Class G		Class H		Class I
		Warrants		Warrants		Warrants			Warrants		Warrants			Warrants		Warrants		Warrants
	Exercise price/share	$	4	$	8	$	2		$	4	$	0.35		$	0.8	$	0.8	$	0.85
	Expiration Date	September		September		January			April		February			July		July		Sept - Dec
		2014		2014		2013			2016		2018			2018		2018		2018

Note_14_Commitments_and_Contin1

Note 14 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Year ending December 31,	Amount
	2014	$	105,643
	2015		90,225
	Total	$	195,868
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	Year ending December 31,	Principal		Interest		Total
	2014	$	3,951	$	125	$	4,076
		$	3,951	$	125	$	4,076

Note_16_Stockbased_Compensatio1

Note 16 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		2013			2012
	Weighted average expected life in years		4.3			5.2
	Weighted average risk free interest rate		0.73	%		0.81	%
	Weighted average volatility		149.85	%		97.83	%
	Forfeiture rate		0	%		0	%
	Expected dividend yield		0	%		0	%
Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]	'
		Unrecognized
		Compensation
	Years ending December 31,	Cost
	2014	$	214,106
	2015		35,151
	Total	$	249,257
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
					Weighted
					Average
					Exercise Price
		Options			per share
	Outstanding at December 31, 2011		4,365,546		$	2.82
	Granted		1,150,000		$	0.23
	Exercised		-		$	-
	Forfeited or expired		(286,216	)	$	2.85
	Outstanding at December 31, 2012		5,229,330		$	2.25
	Granted		4,693,644		$	0.36
	Exercised		(108,334	)	$	0.35
	Cancelled		(1,113,644	)	$	2.92
	Forfeited or expired		(334,166	)	$	1.15
	Outstanding at December 31, 2013		8,366,830		$	1.17
	Vested and exercisable at December 31, 2013		5,112,738		$	1.69
Schedule of Other Share-based Compensation, Activity [Table Text Block]	'
					Weighted
					Average
					Exercise Price
		Options			per share
	Outstanding at December 31, 2011		1,314,722		$	2.48
	Granted		1,150,000		$	0.23
	Vested		(1,901,722	)	$	1.52
	Forfeited or expired		(54,250	)	$	3.41
	Outstanding at December 31, 2012		508,750		$	0.66
	Granted		4,693,644		$	0.36
	Vested		(1,667,886	)	$	0.39
	Cancelled		(43,750	)	$	2.87
	Forfeited or expired		(236,666	)	$	0.5
	Outstanding at December 31, 2013		3,254,092		$	0.35

Note_17_Changes_in_Other_Compr1

Note 17 - Changes in Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
		Currency
		Translations			Total
	Balance, at December 31, 2012	$	13,116		$	13,116
	Other comprehensive loss before reclassifications		(6,428	)		(6,428	)
	Amounts reclassified from AOCI		-			-
	Net change in other comprehensive loss		(6,428	)		(6,428	)
	Balance, at December 31, 2013	$	6,688		$	6,688

Note_1_Summary_of_Significant_1

Note 1 - Summary of Significant Accounting Policies (Details) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 17, 2014

Mar. 17, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Customer 1 [Member]

Customer 1 [Member]

Customer 1 [Member]

Customer 1 [Member]

Customer 2 [Member]

Customer 2 [Member]

Customer 2 [Member]

Customer 2 [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Machinery and Equipment [Member]

Office Equipment [Member]

Furniture and Fixtures [Member]

Vehicles [Member]

Software Development [Member]

Sales Revenue, Goods, Net [Member]

Accounts Receivable [Member]

Patents [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Unsecured 18% Convertible Promissory Notes [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and Cash Equivalents, at Carrying Value (in Dollars)

$182,315

$70,325

$3,909,383

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Working Capital Deficit (in Dollars)

1,700,118

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement (in Dollars)

626,188

'

'

'

'

'

'

'

'

'

'

'

9,280,000

'

'

'

'

'

'

'

'

Proceeds from Convertible Debt (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

815,000

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

18.00%

'

'

'

'

'

'

'

'

'

Number of Major Customers

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

2

'

Concentration Risk, Percentage

'

'

'

28.00%

20.00%

10.00%

6.00%

22.00%

29.00%

11.00%

35.00%

'

'

'

'

'

'

'

'

'

'

Accounts Receivable, Length of Collection Period

'60 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'3 years

'3 years

'3 years

'2 years

'

'

'

Finite-Lived Intangible Asset, Useful Life

'11 years 146 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'11 years 146 days

Notes Payable, Related Parties (in Dollars)

5,372,743

5,372,743

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Rate

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable, Fair Value Disclosure (in Dollars)

$4,653,780

$4,545,620

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)

18,991,971

15,162,069

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_2_Inventory_Details_Inven

Note 2 - Inventory (Details) - Inventory (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory [Abstract]	'	'
Inventory - finished goods	$254,864	$306,706
Inventory - parts	73,142	83,509
Gross inventory	328,006	390,215
Provision for losses and obsolescence	-82,000	-97,550
Net inventory	$246,006	$292,665

Note_3_Property_and_Equipment_1

Note 3 - Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation	$19,575	$20,375

Note_3_Property_and_Equipment_2

Note 3 - Property and Equipment (Details) - Property and Equipment (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$471,962	$505,670
Accumulated depreciation	-458,695	-472,828
Net property and equipment	13,267	32,842
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	233,793	233,793
Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	171,404	179,349
Software Development [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	41,872	41,872
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	22,447	25,679
Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	'	22,531
Property, Plant and Equipment, Other Types [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$2,446	$2,446

Note_4_Intangible_Assets_Detai

Note 4 - Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Disclosure Text Block [Abstract]	'	'
Amortization of Intangible Assets	$306,756	$306,757

Note_4_Intangible_Assets_Detai1

Note 4 - Intangible Assets (Details) - Intangible Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Intangible Assets [Abstract]	'	'
Patents, at cost	$3,502,135	$3,502,135
Less accumulated amortization	-2,581,866	-2,275,110
Net intangible assets	$920,269	$1,227,025

Note_4_Intangible_Assets_Detai2

Note 4 - Intangible Assets (Details) - Amortization Expense (USD $)	Dec. 31, 2013	Dec. 31, 2012
Amortization Expense [Abstract]	'	'
2014	$306,756	'
2015	306,756	'
2016	306,757	'
Total	$920,269	$1,227,025

Note_4_Intangible_Assets_Detai3

Note 4 - Intangible Assets (Details) - Weighted Average Amortization Period for Intangible Assets (USD $)	12 Months Ended
	Dec. 31, 2013
Weighted Average Amortization Period for Intangible Assets [Abstract]	'
Patents	$3,502,135
Patents	'11 years 146 days

Note_5_Accrued_expenses_Detail

Note 5 - Accrued expenses (Details) (President [Member], USD $)	0 Months Ended
	Nov. 06, 2012
President [Member]	'
Note 5 - Accrued expenses (Details) [Line Items]	'
Bonus Payment Amount	$100,000

Note_5_Accrued_expenses_Detail1

Note 5 - Accrued expenses (Details) - Accrued Expenses (USD $)	Dec. 31, 2013	Dec. 31, 2012
Note 5 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued executive severance	$400,000	$542,269
Accrued clinical study expenses	188,927	'
Accrued other	58,812	53,528
	863,572	721,916
Accrued consultants	58,000	'
Accrued board of director's fees	37,333	'
Audit and Tax Preparation [Member]	'	'
Note 5 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued professional fees	91,000	102,600
Legal and Professional Fees [Member]	'	'
Note 5 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued professional fees	$29,500	$23,519

Note_6_Convertible_Promissory_1

Note 6 - Convertible Promissory Note (Details) (USD $)	12 Months Ended	0 Months Ended		1 Months Ended
	Dec. 31, 2013	Feb. 10, 2014	Feb. 10, 2014	Mar. 07, 2014	Mar. 31, 2014	Dec. 23, 2013	Dec. 23, 2013
		Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	During First 60 Days [Member]	8% Convertible Promissory Notes [Member]
		During First 60 Days [Member]	8% Convertible Promissory Notes [Member]	8% Convertible Promissory Notes [Member]		8% Convertible Promissory Notes [Member]
		8% Convertible Promissory Notes [Member]
Note 6 - Convertible Promissory Note (Details) [Line Items]	'	'	'	'	'	'	'
Debt Instrument, Face Amount (in Dollars)	'	'	'	'	'	'	$128,500
Proceeds from Convertible Debt (in Dollars)	'	'	'	110,000	'	'	125,000
Debt Instrument, Maturity Date	'	'	11-Aug-14	'	'	'	26-Sep-14
Debt Instrument, Interest Rate, Stated Percentage	'	'	8.00%	'	'	'	8.00%
Debt Instrument, Prepayment Term	'	'	'180 days	'	'	'	'180 days
Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance	'	120.00%	'	'	'	120.00%	'
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	'	'	75.00%	'	'	'	61.00%
Debt Instrument, Convertible, Threshold Trading Days	'	'	'	'	'	'	10
Repayments of Notes Payable (in Dollars)	$325,000	'	'	'	$158,055	'	'

Note_7_Promissory_Notes_Detail

Note 7 - Promissory Notes (Details) (USD $)	Jul. 09, 2013	Dec. 11, 2013	Dec. 31, 2013	Jul. 09, 2013	Jul. 09, 2013	Aug. 31, 2013	Jul. 09, 2013	Dec. 11, 2013
	Interest Accrued on Unpaid Balance [Member]	Interest Accrued on Unpaid Balance [Member]	Chief Executive Officer [Member]	Chief Executive Officer [Member]	David N. Nemelka [Member]	Promissory Notes [Member]	Promissory Notes [Member]	Promissory Note to Dassity, Inc. [Member]
	Promissory Notes [Member]	Promissory Note to Dassity, Inc. [Member]	Promissory Notes [Member]	Promissory Notes [Member]	Promissory Notes [Member]
Note 7 - Promissory Notes (Details) [Line Items]	'	'	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	'	$360,000	$50,000
Debt Instrument, Interest Rate, Stated Percentage	25.00%	16.00%	'	'	'	'	18.00%	8.00%
Debt Instrument, Term	'	'	'	'	'	'	'179 days	'179 days
Due to Related Parties	'	'	35,000	35,000	100,000	'	'	'
Repayments of Related Party Debt	'	'	'	'	'	325,000	'	'
Interest Expense, Related Party	'	'	'	'	'	$10,664	'	'

Note_8_Senior_Secured_Notes_De

Note 8 - Senior Secured Notes (Details) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended			0 Months Ended	1 Months Ended	12 Months Ended
	Feb. 10, 2014	Jul. 31, 2013	Dec. 31, 2013	Jul. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Mar. 08, 2013	Jul. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
				Class H Warrants [Member]	Class H Warrants [Member]	Board of Directors Chairman [Member]	Board of Directors Chairman [Member]	Senior Secured Notes [Member]	Senior Secured Notes [Member]	Senior Secured Notes [Member]	Senior Secured Notes [Member]
						Senior Secured Notes [Member]
Note 8 - Senior Secured Notes (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	'	'	18.00%	'	'	'
Notes Issued	'	'	'	'	'	'	'	$2,000,000	'	'	'
Debt Instrument, Term	'	'	'	'	'	'	'	'6 months	'	'	'
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	'	'	'	'	'	'	'	$0.20	$0.20	'	'
Debt Conversion, Original Debt, Amount	'	'	'	'	'	64,500	'	4,000,000	'	'	'
Debt Instrument, Convertible, Terms of Conversion Feature, Common Stock Discount	10.00%	'	'	'	'	'	'	20.00%	'	'	'
Secured Debt	'	'	'	'	'	'	'	'	2,186,906	'	'
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	'	'	'	'	'	322,500	'	'	10,934,533	'	'
Warrants Issued (in Shares)	'	'	'	1,988,095	1,988,095	'	58,635	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	'	'	'	0.8	0.8	'	'	'	'	'	'
Warrants Term	'	'	'	'5 years	'	'	'	'	'	'	'
Gains (Losses) on Extinguishment of Debt	'	-1,073,572	-1,073,572	'	'	'	'	'	'	'	'
Share Price (in Dollars per share)	'	$0.60	'	'	'	'	'	'	'	'	'
Fair Value Assumptions, Expected Term	'	'5 years	'	'	'	'	'	'	'	'	'
Fair Value Inputs, Discount Rate	'	1.38%	'	'	'	'	'	'	'	'	'
Fair Value Assumptions, Expected Volatility Rate	'	149.00%	'	'	'	'	'	'	'	'	'
Debt Instrument, Unamortized Discount	'	'	'	'	'	'	'	'	'	2,000,000	'
Embedded Derivative, Fair Value of Embedded Derivative Liability	'	'	'	'	'	'	'	'	'	4,908,000	'
Embedded Derivative, Loss on Embedded Derivative	'	'	2,373,813	'	'	'	'	'	'	2,908,000	'
Embedded Derivative, Fair Value Adjustment Of Embedded Derivative Liability	'	'	'	'	'	'	'	'	'	534,187	'
Debt Instrument, Increase, Accrued Interest	'	'	'	'	'	'	'	'	'	$2,178,390	$8,516

Note_9_Discontinued_Operations2

Note 9 - Discontinued Operations (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2008
Note 9 - Discontinued Operations (Details) [Line Items]	'	'	'
Liabilities of Disposal Group, Including Discontinued Operation, Current	'	$655,061	'
Ossatron Mobile Service Business [Member]	'	'	'
Note 9 - Discontinued Operations (Details) [Line Items]	'	'	'
Liabilities of Disposal Group, Including Discontinued Operation, Current	'	-655,061	655,061
Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, before Income Tax	$655,061	'	'

Note_9_Discontinued_Operations3

Note 9 - Discontinued Operations (Details) - Liabilities Related to Discontinued Operations (USD $)	Dec. 31, 2012	Dec. 31, 2008
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'
Liabilities of discontinued operations	$655,061	'
Ossatron Mobile Service Business [Member]	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'
Accrued expenses	-655,061	'
Liabilities of discontinued operations	($655,061)	$655,061

Note_10_Notes_Payable_Related_2

Note 10 - Notes Payable, Related Parties (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 10 - Notes Payable, Related Parties (Details) [Line Items]	'	'
Related Party Transaction, Rate	6.00%	'
Note Payable To HealthTronics [Member]	'	'
Note 10 - Notes Payable, Related Parties (Details) [Line Items]	'	'
Related Party Transaction, Rate	6.00%	'
Interest Payable, Current	$163,729	$81,864
Interest Payable, Related Parties, Noncurrent	1,372,743	1,372,743
Interest Expense, Related Party	$324,768	$324,768

Note_10_Notes_Payable_Related_3

Note 10 - Notes Payable, Related Parties (Details) - Notes Payable (USD $)	Dec. 31, 2013	Dec. 31, 2012
Notes Payable [Abstract]	'	'
Notes payable, unsecured, payable to Healthtronics, Inc., a shareholder of the Company	$5,372,743	$5,372,743
Non-current portion	$5,372,743	$5,372,743

Note_10_Notes_Payable_Related_4

Note 10 - Notes Payable, Related Parties (Details) - Maturities on Notes Payable, Related Parties (USD $)	Dec. 31, 2013	Dec. 31, 2012
Note 10 - Notes Payable, Related Parties (Details) - Maturities on Notes Payable, Related Parties [Line Items]	'	'
Total	$5,372,743	$5,372,743
Note Payable To HealthTronics [Member]	'	'
Note 10 - Notes Payable, Related Parties (Details) - Maturities on Notes Payable, Related Parties [Line Items]	'	'
2015	5,372,743	'
Total	$5,372,743	'

Note_11_Income_Taxes_Details

Note 11 - Income Taxes (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%

Note_11_Income_Taxes_Details_I

Note 11 - Income Taxes (Details) - Income Tax Provision (Benefit) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current:	'	'
Federal	$0	$0
State	0	0
Foreign	0	0
	0	0
Deferred:	'	'
Federal	-2,116,355	-2,126,006
State	-232,525	-227,883
Foreign	9,144	12,556
Change in valuation allowance	2,339,736	2,341,333
	$0	$0

Note_11_Income_Taxes_Details_R

Note 11 - Income Taxes (Details) - Reconcilation of Income Tax Provision (Benefit) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Reconcilation of Income Tax Provision (Benefit) [Abstract]	'	'
Tax expense (benefit) at statutory rate	($4,184,174)	($2,176,508)
Increase (reduction) in income taxes resulting from:	'	'
State income taxes (benefit), net of federal benefit	-297,680	-159,432
Non-deductible expenses on extinguishment of Senior Secured Notes	1,912,763	'
Income from foreign subsidiaries	22,746	165,660
Change in valuation allowance - United States	2,348,881	2,301,986
Other	197,464	-131,706
Income tax expense (benefit)	$0	$0

Note_11_Income_Taxes_Details_D

Note 11 - Income Taxes (Details) - Deferred Tax Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards	$22,376,888	$20,147,348
Net operating loss carryforwards - foreign	139,529	148,674
Excess of tax basis over book value of property and equipment	30,441	42,946
Excess of tax basis over book value of intangible assets	435,541	431,513
Stock-based compensation	3,396,235	3,097,308
Accrued employee compensation	186,791	352,032
Captialized equity costs	75,471	75,471
Inventory reserve	30,943	36,811
	26,671,839	24,332,103
Valuation allowance	-26,671,839	-24,332,103
Net deferred tax assets	$0	$0

Note_11_Income_Taxes_Details_F

Note 11 - Income Taxes (Details) - Federal Net Operating Loss Carryforwards (USD $)	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	$59,299,144
Expires in 2025 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	1,376,740
Expires in 2026 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	7,291,084
Expires in 2027 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	12,280,771
Expires in 2028 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	6,922,963
Expires in 2029 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	4,816,700
Expires in 2030 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	7,667,557
Expires in 2031 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	8,816,976
Expires in 2032 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	4,768,716
Expires in 2033 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Federal Net Operating Loss Carryforwards	$5,357,637

Note_12_Equity_Transactions_De

Note 12 - Equity Transactions (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

4 Months Ended

12 Months Ended

4 Months Ended

12 Months Ended

4 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Jul. 25, 2013

Dec. 31, 2013

Jul. 25, 2013

Jul. 25, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Public Offering [Member]

Public Offering [Member]

Public Offering [Member]

Public Offering [Member]

Private Placements [Member]

Private Placements [Member]

Private Placements [Member]

Private Placements [Member]

Consulting Agreements [Member]

Class G Warrants [Member]

Class I Warrants [Member]

Common Stock [Member]

Class G Warrants [Member]

Common Stock [Member]

Common Stock [Member]

Class I Warrants [Member]

Class I Warrants [Member]

Common Stock [Member]

Minimum [Member]

Note 12 - Equity Transactions (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

3,006,818

'

3,006,818

'

'

1,043,646

1,043,646

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

'

'

1

'

1

'

1

'

1

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

1,503,409

'

'

'

'

'

'

'

'

'

'

'

Warrants Price Per Unit (in Dollars per Item)

'

'

'

'

'

0.55

'

'

'

0.6

'

'

'

'

Proceeds from Issuance of Public Offering, Gross (in Dollars)

'

'

'

'

'

$1,653,750

'

'

'

'

'

'

'

'

Proceeds from Issuance Public Offering, Net (in Dollars)

'

'

'

'

'

1,517,450

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

0.8

'

'

'

0.85

'

'

'

'

0.8

0.85

'

Class of Warrants or Right, Exercisable Term

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement (in Dollars)

626,188

'

'

'

'

'

'

'

'

626,188

'

'

'

'

Warrants Term

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

Class of Warrant or Right, Call Feature, Stock Price Trigger (in Dollars per share)

'

'

'

'

'

'

'

$1.40

'

'

'

'

'

'

Class of Warrant or Right, Call Feature, Threshold Consecutive Trading Days

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

'

'

'

'

'

'

'

'

'

1,583,315

'

'

1,583,315

Stock Issued During Period, Value, Issued for Services (in Dollars)

$1,014,267

'

'

'

'

'

'

'

'

'

$1,014,267

'

'

$1,584

Preferred Stock, Shares Issued

0

0

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Outstanding

0

0

'

'

'

'

'

'

'

'

'

'

'

'

Note_13_Warrants_Details

Note 13 - Warrants (Details) (Class F Warrants [Member], USD $)	1 Months Ended	7 Months Ended	12 Months Ended
	Feb. 25, 2013	Dec. 31, 2013	Dec. 31, 2013
Class F Warrants [Member]	'	'	'
Note 13 - Warrants (Details) [Line Items]	'	'	'
Warrants Issued	2,000,000	'	2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	0.35	0.35	0.35
Warrants Term	'5 years	'	'
Warrants, Vested During Period	300,000	'	'
Warrants Vesting Contingent Upon Captial Raise Completion	1,700,000	'	'
Capital Raise Threshold for Vesting of Warrants (in Dollars)	$5,000,000	'	'
Warrants Expired	'	1,700,000	1,700,000
Warrants and Rights Outstanding (in Dollars)	'	$300,000	$300,000

Note_13_Warrants_Details_Warra

Note 13 - Warrants (Details) - Warrant Activity

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Feb. 25, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Class A Warrants [Member]

Class A Warrants [Member]

Class A Warrants [Member]

Class B Warrants [Member]

Class B Warrants [Member]

Class B Warrants [Member]

Class D Warrants [Member]

Class D Warrants [Member]

Class D Warrants [Member]

Class E Warrants [Member]

Class E Warrants [Member]

Class E Warrants [Member]

Class F Warrants [Member]

Class F Warrants [Member]

Class F Warrants [Member]

Class G Warrants [Member]

Class H Warrants [Member]

Class H Warrants [Member]

Class I Warrants [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

'

1,950,167

4,235,160

3,576,737

3,576,737

3,576,737

'

300,000

300,000

1,503,409

'

1,988,095

1,043,646

Issued

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

2,000,000

1,503,409

1,988,095

1,988,095

1,043,646

Expired

'

'

'

'

'

'

-1,950,167

-2,284,993

'

'

'

'

'

-1,700,000

-1,700,000

'

'

'

'

Note_13_Warrants_Details_Warra1

Note 13 - Warrants (Details) - Warrant Exercise Price per Share and Expiration Date	12 Months Ended						12 Months Ended			12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Feb. 25, 2013	Dec. 31, 2013	Dec. 31, 2013	Jul. 31, 2013	Dec. 31, 2013
	Class A Warrants [Member]	Class B Warrants [Member]	Class D Warrants [Member]	Class E Warrants [Member]	Class F Warrants [Member]	Class F Warrants [Member]	Class G Warrants [Member]	Class H Warrants [Member]	Class H Warrants [Member]	Class I Warrants [Member]
Note 13 - Warrants (Details) - Warrant Exercise Price per Share and Expiration Date [Line Items]	'	'	'	'	'	'	'	'	'	'
Exercise price/share	4	8	2	4	0.35	0.35	0.8	0.8	0.8	0.85
Expiration Date	'September 2014	'September 2014	'January 2013	'April 2016	'February 2018	'	'July 2018	'July 2018	'	'Sept - Dec 2018

Note_14_Commitments_and_Contin2

Note 14 - Commitments and Contingencies (Details) (USD $)	12 Months Ended						1 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2013	Feb. 16, 2013	Nov. 27, 2012	Nov. 27, 2012	Nov. 27, 2012	Nov. 27, 2012	Dec. 31, 2013	Dec. 31, 2012
				Should Total Available Cash be Less than $100,000 [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]
				Subscription Agreement [Member]	On Or Before January 31, 2013 [Member]	On Or Before February 15, 2013 [Member]	On Or Before May 27, 2014 [Member]
Note 14 - Commitments and Contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)	'	'	'	'	'	'	'	4,000,000	3,600,000	'
Share Price (in Dollars per share)	'	'	$0.60	'	'	'	'	$0.25	'	'
Aggregate Sales Price for Common Stock	'	'	'	'	'	'	'	$1,000,000	'	'
Receivable from Shareholders or Affiliates for Issuance of Capital Stock	'	'	'	100,000	50,000	50,000	900,000	'	900,000	'
Minimum Installment Amount of Purchase Price	'	'	'	'	'	'	100,000	'	'	'
Available Cash, Threshold	'	'	'	'	'	'	'	100,000	'	'
Proceeds from Issuance of Common Stock	1,517,450	'	'	'	'	'	'	'	100,000	25,000
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	'	'	'	'	400,000	100,000
Operating Leases, Rent Expense, Net	124,286	298,452	'	'	'	'	'	'	'	'
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	11,318	6,468	'	'	'	'	'	'	'	'
Capital Leases, Balance Sheet, Assets by Major Class, Net	$3,234	$8,085	'	'	'	'	'	'	'	'

Note_14_Commitments_and_Contin3

Note 14 - Commitments and Contingencies (Details) - Minimum Future Lease Payments under Non-cancelable Operating Leases (USD $)	Dec. 31, 2013
Minimum Future Lease Payments under Non-cancelable Operating Leases [Abstract]	'
2014	$105,643
2015	90,225
Total	$195,868

Note_14_Commitments_and_Contin4

Note 14 - Commitments and Contingencies (Details) - Future Commitments under Capital Lease Agreement (USD $)	Dec. 31, 2013
Note 14 - Commitments and Contingencies (Details) - Future Commitments under Capital Lease Agreement [Line Items]	'
2014	$4,076
	4,076
Principal Payment [Member]	'
Note 14 - Commitments and Contingencies (Details) - Future Commitments under Capital Lease Agreement [Line Items]	'
2014	3,951
	3,951
Interest Payment [Member]	'
Note 14 - Commitments and Contingencies (Details) - Future Commitments under Capital Lease Agreement [Line Items]	'
2014	125
	$125

Note_15_401k_Plan_Details

Note 15 - 401(k) Plan (Details) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Disclosure Text Block Supplement [Abstract]	'	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%	'	'
Defined Contribution Plan, Cost Recognized	'	$0	$9,664

Note_16_Stockbased_Compensatio2

Note 16 - Stock-based Compensation (Details) (USD $)

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Feb. 25, 2013

Feb. 25, 2013

Feb. 25, 2013

Feb. 25, 2013

Nov. 06, 2012

Nov. 06, 2012

Feb. 25, 2013

Feb. 25, 2013

Nov. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Nov. 06, 2012

Nov. 06, 2012

Sep. 03, 2013

Feb. 21, 2013

Feb. 21, 2013

Mar. 08, 2012

Feb. 21, 2013

Feb. 25, 2013

Dec. 31, 2013

Dec. 31, 2012

Feb. 21, 2013

Feb. 25, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 08, 2012

Vested at Grant [Member]

Options Vesting Upon Company Completing $5.0 Million Gross Proceeds [Member]

Options Vesting Upon Company Completing $1.0 Million Gross Proceeds [Member]

Options Vesting Upon Company Completing $1.0 Million Gross Proceeds [Member]

Upon Events Tied To Clinical Trial Plan for DermaPACE Device [Member]

Upon Events Tied To Clinical Trial Plan for DermaPACE Device [Member]

Upon Events Tied To Clinical Trial Plan for DermaPACE Device [Member]

Upon Achieveing All Milestones During Initial Two Year Term and the Term is Not Extended by Company [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Consideration for Provision of Advisory Services [Member]

Severance Agreement with Mr. Cashman [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Members of Medical Advisory Board [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Severance Agreement with Mr. Cashman [Member]

Severance Agreement with Mr. Cashman [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Severance Agreement with Mr. Cashman [Member]

New Member of Board of Directors [Member]

Active Employees and Directors [Member]

Each Member of Medical Advisory Board [Member]

Each Member of Medical Advisory Board [Member]

Members of Medical Advisory Board [Member]

Chief Executive Officer [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Minimum [Member]

Vesting in Increments [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Note 16 - Stock-based Compensation (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'3 years

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

8,500,000

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

4,693,644

1,150,000

'

'

'

'

'

'

'

'

'

'

'

'

50,000

1,000,000

100,000

2,243,644

50,000

50,000

'

2,250,000

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$0.36

$0.23

'

'

'

'

'

'

'

'

'

'

'

'

$0.21

$0.21

$0.65

$0.35

$0.35

$0.44

'

$0.35

'

'

'

$0.35

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

$0.60

$0.22

$0.64

$0.27

'

$0.21

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

$792,160

$1,391,316

'

$160,500

$60,000

$499,621

'

'

$64,000

$465,000

'

'

'

'

'

'

'

'

$27,250

Share-Based Compensation Arrangement, By Share-Based Payment Award, Options, Cancel In Period (in Shares)

43,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,113,644

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price Per Share

$2.87

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.92

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Options Vesting (in Shares)

'

'

'

375,000

375,000

375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Receipt For Option Vesting Threshold (in Dollars)

'

'

'

'

5,000,000

1,000,000

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod (in Shares)

'

'

'

'

'

'

'

'

'

375,000

750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares)

1,667,886

1,901,722

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)

'

'

'

'

'

'

'

100,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

$1.17

$2.25

$2.82

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.21

$0.44

$2.92

$4.05

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

92,030

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,271,540

0

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$574,181

$0

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years 350 days

'6 years 229 days

'

'

'

'

'

'

'

Note_16_Stockbased_Compensatio3

Note 16 - Stock-based Compensation (Details) - Fair Value Assumptions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Assumptions [Abstract]	'	'
Weighted average expected life in years	'4 years 109 days	'5 years 73 days
Weighted average risk free interest rate	0.73%	0.81%
Weighted average volatility	149.85%	97.83%
Forfeiture rate	0.00%	0.00%
Expected dividend yield	0.00%	0.00%

Note_16_Stockbased_Compensatio4

Note 16 - Stock-based Compensation (Details) - Unrecognized Compensation Cost (USD $)	Dec. 31, 2013
Note 16 - Stock-based Compensation (Details) - Unrecognized Compensation Cost [Line Items]	'
Unrecognized compensation cost	$249,257
Will Be Recognized in 2014 [Member]	'
Note 16 - Stock-based Compensation (Details) - Unrecognized Compensation Cost [Line Items]	'
Unrecognized compensation cost	214,106
Will Be Recognized in 2015 [Member]	'
Note 16 - Stock-based Compensation (Details) - Unrecognized Compensation Cost [Line Items]	'
Unrecognized compensation cost	$35,151

Note_16_Stockbased_Compensatio5

Note 16 - Stock-based Compensation (Details) - Option Activity (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Option Activity [Abstract]	'	'	'
Outstanding number	8,366,830	5,229,330	4,365,546
Outstanding weighted average exercise price per share	$1.17	$2.25	$2.82
Vested and exercisable at December 31, 2013	5,112,738	'	'
Vested and exercisable at December 31, 2013	$1.69	'	'
Granted number	4,693,644	1,150,000	'
Granted weighted average exercise price per share	$0.36	$0.23	'
Exercised number	-108,334	'	'
Exercised weighted average exercise price per share	$0.35	'	'
Cancelled	-1,113,644	'	'
Cancelled	$2.92	'	'
Forfeited or expired number	-334,166	-286,216	'
Forfeited or expired weighted average exercise price per share	$1.15	$2.85	'

Note_16_Stockbased_Compensatio6

Note 16 - Stock-based Compensation (Details) - Nonvested Options Activity (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Nonvested Options Activity [Abstract]	'	'	'
Outstanding number	3,254,092	508,750	1,314,722
Outstanding weighted average exercise price per share	$0.35	$0.66	$2.48
Granted number	4,693,644	1,150,000	'
Granted weighted average exercise price per share	$0.36	$0.23	'
Vested number	-1,667,886	-1,901,722	'
Vested weighted average exercise price per share	$0.39	$1.52	'
Cancelled	-43,750	'	'
Cancelled	$2.87	'	'
Forfeited or expired number	-236,666	-54,250	'
Forfeited or expired weighted average exercise price per share	$0.50	$3.41	'

Note_17_Changes_in_Other_Compr2

Note 17 - Changes in Other Comprehensive Loss (Details) - Other Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Other comprehensive income/loss	$6,688	$13,116
Other comprehensive loss before reclassifications	-6,428	'
Net change in other comprehensive loss	-6,428	'
Accumulated Translation Adjustment [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Other comprehensive income/loss	6,688	13,116
Other comprehensive loss before reclassifications	-6,428	'
Net change in other comprehensive loss	($6,428)	'

Note_18_Segment_and_Geographic1

Note 18 - Segment and Geographic Information (Details) (Europe, Asia and Asia/Pacific [Member])	12 Months Ended
	Dec. 31, 2013
Europe, Asia and Asia/Pacific [Member]	'
Note 18 - Segment and Geographic Information (Details) [Line Items]	'
Number of Operating Segments	1

Note_19_Subsequent_Events_Deta

Note 19 - Subsequent Events (Details) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Feb. 10, 2014

Dec. 31, 2013

Feb. 10, 2014

Feb. 18, 2014

Mar. 17, 2014

Mar. 17, 2014

Mar. 17, 2014

Mar. 17, 2014

Mar. 17, 2014

Mar. 17, 2014

Mar. 17, 2014

Mar. 17, 2014

Feb. 28, 2014

Mar. 17, 2014

Mar. 17, 2014

Feb. 10, 2014

Mar. 17, 2014

Mar. 07, 2014

Feb. 10, 2014

Mar. 07, 2014

Feb. 10, 2014

Feb. 18, 2014

Mar. 17, 2014

Dec. 23, 2013

Dec. 31, 2013

Dec. 23, 2013

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

During First 60 Days [Member]

Common Stock [Member]

8% Convertible Promissory Notes [Member]

During First 60 Days [Member]

During First 60 Days [Member]

The 2014 Private Offering [Member]

The 2014 Private Offering [Member]

The 2014 Private Offering [Member]

The 2014 Private Offering [Member]

The 2014 Private Offering [Member]

The 2014 Private Offering [Member]

The 2014 Private Offering [Member]

The 2014 Private Offering [Member]

Consulting Agreements [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Class J Warrants [Member]

18% Convertible Promissory Notes [Member]

18% Convertible Promissory Notes [Member]

8% Convertible Promissory Notes [Member]

8% Convertible Promissory Notes [Member]

8% Convertible Note and Class J Warrants [Member]

$78,500 Convertible Note [Member]

8% Convertible Promissory Notes [Member]

8% Convertible Promissory Notes [Member]

$78,500 Convertible Note [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Common Stock [Member]

Convertible Preferred Stock [Member]

Board of Directors Chairman [Member]

Chief Executive Officer [Member]

Michael N. Nemelka [Member]

Note 19 - Subsequent Events (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

'

'

'

'

'

6,210,000

6,175

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement

'

$626,188

'

'

'

'

'

'

$50,000

$40,000

$50,000

$9,280,000

'

'

'

'

'

'

'

'

'

'

$9,280,000

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding (in Shares)

'

'

'

'

23,200,000

13,920,000

'

'

'

'

'

'

'

2,055,421

1,233,252

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

0.5

1.5

'

'

'

'

'

'

'

'

'

0.4425

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

1

1

'

'

'

'

'

'

'

'

'

629,378

'

'

'

'

'

'

'

'

'

'

Class of Warrants or Right, Exercisable Term

'

'

'

'

'5 years

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18.00%

8.00%

'

'

8.00%

'

'

'

8.00%

Maximum Amount of Secured Notes Authorized to Issue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

815,000

'

'

278,500

78,500

'

'

'

128,500

Proceeds from Convertible Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110,000

250,000

75,000

'

'

'

125,000

Debt Instrument, Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 months

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.55

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

822,168

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,644,337

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Terms of Conversion Feature, Common Stock Discount

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11-Aug-14

'

'

20-Nov-14

'

'

'

26-Sep-14

Debt Instrument, Original Issuance Discount, Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000

'

'

'

'

'

'

'

Debt Instrument, Prepayment Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'180 days

'

'

'180 days

'

'

'

'180 days

Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance

'

'

120.00%

120.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

120.00%

'

'

Debt Instrument, Convertible, Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'180 days

'

'

'180 days

'

'

'

'

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75.00%

'

'

61.00%

'

'

'

61.00%

Debt Instrument, Convertible, Threshold Consecutive Trading Days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'

'

'10 years

'

'

'

'

Period After Closing Date Warrants Become Exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

Warrants Expiration Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'five

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)

'

'

'

'

0.5

1.5

'

'

'

'

'

'

'

'

'

0.4425

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

835,000

'

'

'

'

'

'

'

'

'

'

'

1,583,315

'